Stockwinners Market Radar for October 26, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:35 EDT Ingersoll-Rand initiates quarterly dividend of 2c per share - The dividend is payable on December 17, 2021, to stockholders of record on November 10, 2021. The company states: "This is the first quarterly dividend to be paid by the company as part of its new dividend program, which was recently announced during the presentation of its M&A-focused capital allocation strategy at an investor call on September 2, 2021."

18:23 EDT Logitech CEO: We're in a good position from a secular growth standpoint - In an interview on CNBC's Mad Money, Bracken Darrell said almost all of Logitech's businesses are in the secular growth box. "We feel good about the momentum in video collaboration," he added. The company is putting more into inventory to offset supply chain issues. According to Darrell, Logitech is not immune to supply chain challenges, but it will be prepared for the holidays. He expects to use more air freight, which will likely impact margins.

18:22 EDT Popular exec chairman Carrion sells 25,286 common shares - In a regulatory filing, Popular executive chairman Richard Carrion disclosed the sale of 25,286 common shares of the company on October 26, 2021 at a price of $85.059 per share.

18:17 EDT Twitter says it's moving fast to adapt to Apple tracking changes - Twitter (TWTR) says moving fast to adapt to Apple (AAPL) tracking changes. Says has "so much more work to do" in terms of machine learning.

18:10 EDT Silvergate Capital director Reed sells 7,522 class A shares - In a regulatory filing, Silvergate Capital director Scott Reed disclosed the sale of 7,522 class A common shares of the company at a price of $150.1109 per share.

18:01 EDT Stratus Properties to sell Block 21 for $260M to Ryman Hospitality - Stratus Properties "announced that it has agreed to sell Block 21, a mixed-use entertainment, lodging, office and retail complex located in downtown Austin, Texas, to Ryman Hospitality Properties, Inc. for $260M. Stratus previously announced an agreement to sell Block 21 to Ryman for $275M in December 2019, which was terminated in May 2020 by Ryman due to the intervening COVID-19 pandemic. As a result of the termination, Ryman forfeited $15M of earnest money to Stratus."

17:55 EDT Microsoft CFO says Q1 commercial bookings grew 14%, RPO up 29% in constant FX - Says Windows OEM performance was better than expected in a growing PC market despite ongoing supply chain strengths. Says in gaming, we were able to ship more Xbox Series X and S consoles than expected even as demand continues to exceed supply.

17:44 EDT Microsoft CEO says LinkedIn saw record engagement in the quarter - Says Microsoft Teams usage has never been higher. Says Teams has become first-class platform for application development. Comments taken from Q1 earnings conference call.

17:39 EDT Fulton Financial CLO Daniel Stolzer to retire on January 7, 2022 - Daniel R. Stolzer, senior executive vice president, chief legal officer and corporate secretary of Fulton Financial Corporation, has announced that he will retire from Fulton on January 7, 2022 after more than eight years of service to the company. In a related announcement, Fulton announced that Natasha R. Luddington has joined Fulton's senior management team as senior executive vice president and will become the corporation's chief legal officer and corporate secretary upon Stolzer's retirement.

17:17 EDT Raytheon Technologies awarded $340M Air Force contract - Raytheon has awarded a $340M firm-fixed-price, cost-reimbursable, indefinite-delivery/indefinite-quantity contract for mobile sensors operations and maintenance services of the Cobra King radar system. Work will be performed at Patrick Space Force Base, Florida, and outside continental U.S. locations, and is expected to be completed by October 31, 2031. This award is the result of a competitive acquisition in which one offer was received. FY22 operations and maintenance funds in the amount of $17.7M are being obligated at the time of award. Acquisition Management and Integration Center is the contracting activity.

17:10 EDT Navient reports Q3 loan delinquency 8.5% vs. 9.3% last year - Reports Q3 Private Education Loan delinquency rate increased from 2.4% to 3.0% y/y and delinquencies greater than 30 days were $3.8B compared with $4.5B y/y.

17:03 EDT Curaleaf begins sale of whole flower at New York locations - Curaleaf announced that its initial batches of New York whole flower have cleared testing by third party labs and that sales of three initial strains will begin this afternoon in company's Newburgh location and tomorrow afternoon in Curaleaf's Carle Place, Forest Hills, and Plattsburgh dispensaries. Prior to this month, cannabis was only available to New York patients in ground form.

16:58 EDT Alphabet says there is unevenness in recovery of global economy - Says Android 12 is the biggest design change in Android history. Says Q3 cloud revenue grew 45% year-over-year. Says surpassed 50M music and streaming subscribers on Youtube. Says Waymo will open trucking hub in Dallas-Forth Worth area next year. Says business in APAC is growing really well. Says there is unevenness in recovery of global economy. Says has seen explosive growth in digital over past 20 months, but brick and mortar is not dead. Says expects no foreign exchange impact in Q4. Says expects drivers of revenue in Q4 to be hardware and YouTube subscriptions. Comments taken from Q3 earnings conference call.

16:47 EDT Teva, MODAG announce licensing collaboration for anle138b and sery433 - Teva and MODAG announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG's lead compound anle138b and a related compound, sery433. Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with neurodegenerative diseases for potential disease modification. Under the terms of the agreement and pending regulatory clearance, Teva will receive an exclusive global license to develop, manufacture and commercialize anle138b and sery433. The companies will jointly develop the compounds for the multiple system atrophy, or MSA, and Parkinson's disease, or PD, indications based on early-stage clinical studies, and consider exploring additional indications based on clinical outcomes. A Phase 1 study examining anle138b in healthy volunteers completed in July 2020 demonstrated benefit-risk profile at all dose levels while achieving higher plasma levels than those required for full therapeutic efficacy in animal models. Anle138b was initially developed in patients with MSA and PD and has the potential to be applied to other neurodegenerative disorders, such as Alzheimer's disease. A Phase 1b clinical trial evaluating the safety of the compound, as well as efficacy measures in patients living with PD, is currently being conducted.

16:39 EDT Bioventus, Misonix stockholders approve previously announced merger pact - Bioventus (BVS) and Misonix (MSON) announced that the stockholders of Bioventus approved the issuance of shares of Bioventus class A common stock to the stockholders of Misonix in connection with the previously announced Agreement and Plan of Merger, dated July 29, by and among Bioventus, Misonix and other parties thereto, pursuant to which Misonix will be acquired by, and become a wholly-owned subsidiary of, Bioventus and the stockholders of Misonix have approved the proposal to adopt the Merger Agreement.

16:33 EDT First Bank declares quarterly dividend of 6c per share - On October 19, First Bank's Board of Directors declared a quarterly cash dividend of 6c per share to common stockholders of record at the close of business on November 5, payable on November 19. This reflects a 100% increase from the dividend declared during the linked and prior year quarters and represents an annualized yield of 1.57% based on upon the $15.25 closing price of the Bank's stock on October 19.

16:33 EDT Delek Logistics raises quarterly distribution 1.1% to 95c per unit - Delek Logistics Partners declared its quarterly cash distribution for the third quarter 2021 of 95c per common limited partner unit, or $3.80 per common limited partner unit on an annualized basis. This distribution represents a 1.1% increase from the distribution for the second quarter 2021 of 94c per common limited partner unit and a 5% increase over Delek Logistics' distribution for the third quarter 2020 of 90.5c per common limited partner unit. The third quarter 2021 cash distribution is payable on November 10, 2021 to unitholders of record on November 5, 2021. "This sustains a consistent quarterly increase since the fourth quarter 2012 in the cash distribution and demonstrates stability of the business throughout various business cycles. Industry trends are positive with healthy margins driving strong utilization rates of refining and logistics assets. These macro dynamics provide us with confidence in the outlook for DKL," said Uzi Yemin, Chairman, President and Chief Executive Officer of Delek Logistics.

16:32 EDT DBV Technologies drops 11% to $4.50 after detailing FDA feedback

16:32 EDT DBV says FDA requested stepwise approach to Viaskin program - DBV Technologies said that on October 14, it received communication from the FDA concerning the STAMP protocol submission of May 6, 2021. The FDA has requested a stepwise approach to DBV's modified Viaskin Peanut development program. The FDA would like to review the data from DBV's protein uptake release study prior to providing additional comments on the STAMP protocol design, it added. In its communication, FDA stated that guidance is forthcoming on how best to demonstrate the protein uptake comparability of the mVP to the reference or current patch. The STAMP trial will not be initiated until DBV receives complete feedback from the FDA. "DBV is working hard to find an efficient and timely path forward. On behalf of patients and providers urgently awaiting a therapeutic advancement in treating peanut allergy, DBV will continue to pursue our goal of bringing Viaskin Peanut to the food allergy community," said Daniel Tasse, CEO.

16:31 EDT American Electric to sell Kentucky operations to Algonquin unit for $2.846B - American Electric Power (AEP) has entered into an agreement to sell its Kentucky operations, which include Kentucky Power and AEP Kentucky Transco, to Liberty, the regulated utility business of parent company Algonquin Power & Utilities Corp. (AQN), for $2.846B enterprise value. The sale is expected to close in the second quarter of 2022, pending regulatory approvals. AEP announced in April 2021 that the company was conducting a strategic review of its Kentucky operations, including a potential sale, and held a competitive process as part of the review."Kentucky Power and its employees are an important part of the communities in eastern Kentucky, and I am grateful for their valuable contributions to AEP," said Nicholas K. Akins, AEP chairman, president and chief executive officer. "Liberty's commitment to safety and operational excellence will allow Kentucky Power employees to continue their critical work producing and delivering reliable power for customers and communities. At the same time, the sale will strengthen AEP's ability to invest in projects that will support a resilient, cleaner energy system."

16:30 EDT Valaris announces contract with Esso Exploration Angola for drillship - Valaris Limited announced that it has been awarded a two-year contract with Esso Exploration Angola, an affiliate of ExxonMobil, offshore Angola for drillship VALARIS DS-9. The rig is currently preservation stacked in the Canary Islands, where it will be reactivated and then mobilized to Angola ahead of the anticipated contract commencement in June 2022.

16:28 EDT EVgo, GM open new EV charging station in Colorado - EVgo (EVGO) announced the opening of a new EV charging station comprised of six new EVgo public direct current fast chargers at Lloyd King Center, located at 6350 Sheridan Boulevard in Arvada, Colorado. "The opening of another EVgo charging station in Colorado builds upon GM (GM) and EVgo's effort to accelerate charging infrastructure build out by adding more than 2,700 DC fast charging stations. Along with all the Ultium-ready chargers at EVgo stations, GM customers can leverage charging capabilities up to 350-kilowatts," said Alex Keros, Lead Architect, EV Infrastructure at General Motors. "We are excited to partner with EVgo to expand charging access here in the Rocky Mountain State and across the country."

16:27 EDT Getty Realty raises quarterly dividend 5.1% to 41c per share - Getty Realty Corp. announced that its Board of Directors declared a cash dividend of 41c per common share, an increase of 5.1% over the previous quarterly dividend. The dividend is payable on January 6, 2022 to holders of record on December 23, 2021.

16:24 EDT Waste Connections reports reduction in emissions, progress towards ESG targets - Waste Connections announced the release of its 2021 Sustainability Report demonstrating progress towards all of its long-term, aspirational sustainability targets, as well as an 8% reduction in operational greenhouse gas emissions. The updated report also provides expanded disclosure illustrating the company's commitment to environmental stewardship, the health, welfare and development of its employees, and the support of its local communities. Reference Link

16:22 EDT Visa increases quarterly cash dividend 17% to 37.5c per share - On October 22, the board of directors declared an increase to Visa's quarterly cash dividend to 37.5c per share of class A common stock, payable on December 7 to all holders of record as of November 12.

16:21 EDT AMD up 1.8% after reporting better-than-expected Q3 earnings, Q4 guidance

16:19 EDT FDA panel votes in support of Pfizer-BioNTech vaccine for kids aged 5-11 - An FDA Advisory Committee voted 17 yes to 0 no with 1 abstention that the totality of scientific evidence available supports the benefits of the Pfizer (PFE) and BioNTech (BNTX) COVID vaccine when administered as a 2-dose series outweigh its risks for use in children 5-11 years of age.

16:18 EDT Nabors Industries sees FY21 CapEx 270M - Capital expenditures for the full year are expected to total approximately $270M, including approximately $90M supporting SANAD's newbuild rig program. This translates into targeted fourth quarter capital expenditures of $91M, of which $32M is for SANAD newbuilds.

16:15 EDT Visa reports Q4 payments volume up 17% on constant-dollar basis - Reports Q4 payments volume up 17% year-over-year in constant dollars, cross-border volume excluding intra-Europe up 46%, cross-border volume total up 38% and processed transactions up 21%.

16:12 EDT NCR Corp. sees being at lower end of 2H outlook - The company previously forecast 2H adjusted EPS $1.30-$1.50, revenue $4B-$4.1B, adjusted EBITDA $700M-$750M and free cash flow of $325M-$375M.

16:12 EDT Texas Instruments says analog revenue grew 24% in Q3 - Regarding the company's performance and returns to shareholders, Rich Templeton, TI's chairman, president and CEO, made the following comments: "Revenue increased 22% from the same quarter a year ago due to strong demand in industrial, automotive and personal electronics. Analog revenue grew 24% and Embedded Processing grew 13% from the same quarter a year ago. Our cash flow from operations of $8.5 billion for the trailing 12 months again underscored the strength of our business model. Free cash flow for the same period was $7.1 billion and 41% of revenue. This reflects the quality of our product portfolio, as well as the efficiency of our manufacturing strategy, including the benefit of 300-millimeter production. We returned $4.2 billion to owners in the past 12 months through dividends and stock repurchases. Over the same period, our dividend represented 53% of free cash flow, underscoring its sustainability. In September, we announced we would increase our dividend by 13%."

16:10 EDT Microsoft to provide forward-looking guidance on earnings conference call

16:10 EDT Microsoft returned $10.9B to shareholders in Q1 - Microsoft said it returned $10.9 billion to shareholders in the form of share repurchases and dividends in the first quarter of fiscal year 2022, an increase of 14% compared to the first quarter of fiscal year 2021. "We delivered a strong start to the fiscal year with our Microsoft Cloud generating $20.7 billion in revenue for the quarter, up 36% year over year," said Amy Hood, executive vice president and chief financial officer of Microsoft.

16:08 EDT Alphabet CFO says investments for long-term growth reflected in performance - Ruth Porat, CFO of Alphabet and Google, said: "Our consistent investments to support long-term growth are reflected in strong financial performance, with revenues of $65.1 billion in the quarter. We continued to deliver across our business by providing helpful and valuable experiences for both consumers and our partners."

16:08 EDT C.H. Robinson CEO says capacity to remain tight - CEO Bob Biesterfeld says: "Our strong financial results demonstrate that our integrated services model is working. Given the current structural constraints around expansion of supply, coupled with continued strong demand as we head into the holiday season, we expect capacity to remain tight and to perform well in that environment. We'll continue to leverage the strength of our diversified non-asset-based business model that delivers strong returns on invested capital. We'll stay the course with our strategy of pursuing market share gains that align with our profitability expectations, and we'll continue to invest back into the business, in order to drive innovation, improve service to our customers and carriers, and drive growth across our global suite of modes and services."

16:08 EDT Alphabet reports Q3 Traffic Acquisition Costs $11.5B vs. $8.17B a year ago

16:07 EDT Alphabet reports Q3 Google Cloud revenue $4.99B vs. $3.44B a year ago

16:04 EDT Microsoft reports Q1 Product revenue $16.63B, Intelligent Cloud revenue $16.96B

16:02 EDT Cortexyme says co-primary endpoints not met in Phase 2/3 GAIN trial - Cortexyme reported top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat, an investigational orally administered small-molecule that targets gingipain proteases from the bacterium Porphyromonas gingivalis. The 643-participant study in mild to moderate patients with Alzheimer's disease did not meet statistical significance in its co-primary cognitive and functional endpoints as measured by ADAS-Cog11 and ADCS-ADL at end of the treatment period in the overall cohort. The pre-specified subgroup of participants with P. gingivalis DNA detectable in saliva at baseline showed a dose response, with a 57% slowing of cognitive decline as measured by ADAS-Cog11 in the 80 mg BID arm and a 42% slowing in the 40 mg BID arm vs. placebo. Significant benefits in this subgroup were not seen on the other co-primary, ADCS-ADL. The cognitive benefit of atuzaginstat in patients with high P. gingivalis infection was reinforced by similar results in multiple pre-specified infection related subgroups and with multiple methods of analysis. Additionally, reductions in P. gingivalis in saliva at week 24 were significantly correlated with improved outcomes at the end of the treatment period as measured by ADAS-Cog11, Clinical Dementia Rating-Sum of Boxes, Mini-Mental State Exam, and a beneficial trend on ADCS-ADL. The sub-study in periodontal disease demonstrated a trend to benefit on the primary clinical endpoint of pocket depth in the same pre-specified sub-group with P. gingivalis DNA detectable in saliva. Further results will inform the next stage of development in periodontitis and will be presented at a future scientific conference.

15:41 EDT MP Materials says Grizzly's 'report' gets 'facts & analysis wrong' - MP Materials stated in a series of tweets on its official Twitter account in response to a short report published this morning: " "We welcome @ResearchGrizzly to the long list of entities who have doubted $MP's ability to execute and consistently been proven wrong. Grizzly's 'report' gets the facts & analysis wrong and displays a fundamental misunderstanding of our business, industry & performance. [...] Just one example: Grizzly claims MP 'mostly mines less valuable rare earth (sp), namely Cerium and Lanthanum."' They fail to understand that all scaled rare earth deposits produce more abundant quantities of lower value rare earths, *hence why* they are lower value. {} But the high value elements, namely Nd and Pr, drive the value of our basket. [...] We take great pride in communicating clearly & transparently with stakeholders through our public filings & communications. It's disappointing to see entities misrepresent and sensationalize aspects of our business. Ultimately, it's a distraction. But we are not dissuaded. [...] We report Q3 2021 earnings after the U.S. markets close on Thursday, November 4th, 2021, and look forward to updating all of our shareholders on the state of our business and industry." Reference Link

14:51 EDT Legendary confirms 'Dune Part Two' in the works - Legendary Pictures confirmed that "Dune Part Two," a sequel to the Denis Villenueve-directed "Dune" which came out last week, is currently in the works. The latest adaptation of the Frank Herbert novel was distributed by Warner Bros. Pictures, a subsidiary of AT&T. Reference Link

14:36 EDT Seadrill announces plan of reorganization confirmred by U.S. Bankruptcy Court - Seadrill Limited announces that its Plan of Reorganization has been confirmed by the U.S. Bankruptcy Court for the Southern District of Texas. "Earlier this month, the Plan received overwhelming support from the Company's stakeholders. Following the Court's approval of the Plan, Seadrill is targeting an exit of Chapter 11 proceedings in approximately 60 days. This is subject to certain customary conditions, including certain antitrust approvals. The Plan raises $350M in new financing and reduces the Company's existing liabilities by $4.9B, while leaving employee, customer, and trade claims unaffected. Existing shareholders will see their holding in the post emergence entity decrease to 0.25%. Commentingy, Stuart Jackson, Seadrill Chief Executive Officer, said: "Confirmation of the Plan by the Court is a watershed moment for Seadrill and one we should celebrate as we move into the final stages to emerge from Chapter 11. Achieving this milestone would not be possible without the collective efforts of our employees, customers, partners, suppliers, creditors and shareholders. The continued support from this broad Seadrill community is one of our greatest assets and will be critical to the success of our next chapter as we reinforce our position as a market leader. "With emergence around the end of the year, we stand alongside our offshore drilling peers focused on safe and efficient delivery to our customers in an industry that continues to need to evolve. Seadrill's strong brand will ensure we maintain a leadership position in future developments."

13:16 EDT Walmart says expanding in-store bill payment services with InComm Payments - Walmart and InComm Payments announced "a more convenient and efficient way for millions of customers to pay their bills or fund prepaid accounts nationwide" at more than 4,700 Walmart locations in the U.S. through VanillaDirect. Walmart said: "Bringing this service to Walmart stores creates additional convenience for Walmart shoppers by allowing them to quickly and easily pay bills or fund accounts in the InComm Payments VanillaDirect network which includes more than 15,000 billers and account providers across a variety of sectors, such as utility, telecommunication, tolling, banking, rental companies and insurance providers. The offering adds to the retailer's already extensive financial services and shows Walmart's continued commitment to serving un- and under-banked customers." Reference Link

12:16 EDT Trex Company announces plans for third U.S. production site - Trex Company has announced plans to develop a new multi-faceted production site in Little Rock, Ark. The company, which continues to experience broad-based demand driven by increasing consumer interest in outdoor living, believes that building a third U.S.-based manufacturing facility should enable the company to provide customers significantly better access to Trex Residential products where and when they need them, and position the company for future growth. Trex believes the new production complex, to be located within the Port of Little Rock, should increase the company's ability to meet the anticipated strong demand for its industry-leading decking and railing products. Based on the company's search parameters, Little Rock emerged as the best fit for Trex's immediate and future needs with a location closer to essential raw materials, a strong pool of qualified and skilled labor, proximity to key growth regions for wood conversion, and adjacency to major transportation hubs that will offer optimized freight costs for customers in the middle of the country who are presently served by existing facilities in Virginia and Nevada. Adding capacity also positions the company to better serve its distribution and retail partners domestically and abroad. Trex expects to invest an estimated $400M over the next five years in the development of the new Arkansas site, funded primarily through ongoing cash generation. The Trex campus will sit on nearly 300 acres of land and will eventually include buildings dedicated to decking and railing production, plastic film recycling and processing, reclaimed wood storage, warehousing and administrative offices. Construction is slated to begin in early 2022. The development approach will be modular and calibrated to demand trends with the first production output anticipated in 2024. The campus will substantially expand output and will have the potential to be the company's largest manufacturing facility.

12:01 EDT Turning Point Brands falls -17.7% - Turning Point Brands is down -17.7%, or -$8.60 to $40.01.

12:00 EDT Stem rises 11.2% - Stem is up 11.2%, or $2.59 to $25.74.

12:00 EDT Shapeways rises 13.3% - Shapeways is up 13.3%, or 95c to $8.09.

11:25 EDT Fox says Fox Nation to launch on YouTube TV as add-on option - Fox News Media's (FOXA) streaming service, "Fox Nation," is launching on Google's (GOOGL) YouTube TV as an optional add on starting today, announced Jason Klarman, president of the service. Beginning today, YouTube TV subscribers will have the option to add Fox Nation to their YouTube TV subscription for $5.99 a month, the company noted. In making the announcement, Klarman said, "We're thrilled to partner with YouTube TV to bring FOX Nation to their cutting edge TV service and provide our passionate audience with more ways to enjoy the original content they desire."

11:09 EDT MP Materials down 5% after Grizzly calls for 60% downside in short report - Shares of rare earth miner MP Materials, which came public in November 2020 through a SPAC merger backed by Chamath Palihapitiya, are sliding after the stock was the focus of a new short report by Grizzly Research. MP has claimed to be the biggest rare earth producer in the western world, but the firm believes "that this is nothing more than a smoke and mirrors show," Grizzly stated. The firm alleges that Shenghe, "a related party that accounts for 99% of MP's revenue, and a significant shareholder, can be traced back to the Chinese central government." MP is "the second iteration of the same mining venture (Molycorp) that previously ended in bankruptcy," said Grizzly, which sees about "60% downside in the short to medium term once investors and regulators wake up to the company's shenanigans." In morning trading following the publication of the short report, MP shares are down $1.82, or 5%, to $36.28. Reference Link

11:05 EDT Lockheed Martin sees multiple programs entering production from 2023-2026

11:04 EDT Lockheed Martin sees sales increasing 'slightly' in 2023

10:53 EDT Ocugen trading resumes

10:39 EDT F.N.B. reports final regulatory approval for Howard Bancorp merger - F.N.B. Corporation (FNB) announced it has received all regulatory clearances for its proposed merger with Howard Bancorp (HBMD). "The merger between FNB and Howard will further strengthen FNB's presence in its Mid-Atlantic Region, with the combined organization projected to assume the sixth largest deposit share position in Baltimore, MD. FNB continues to expect the merger to be 4 percent accretive to earnings per share with fully phased-in cost savings on a GAAP basis and expects the merger to enhance FNB's profitability metrics. Additionally, FNB anticipates the tangible book value per common share impact to be minimal and expects the CET1 ratio to remain unchanged on a pro forma basis at closing," the company said. The completion of the merger remains subject to the satisfaction of certain routine and customary closing conditions and approval by Howard stockholders, who will vote on the proposed merger at a special meeting scheduled for November 9. The respective Boards of Directors of Howard and FNB have previously approved the agreement and Plan of Merger between FNB and Howard. As announced on July 13, 2021, Howard stockholders will be entitled to receive 1.8 shares of FNB common stock for each share of Howard common stock they own. The exchange ratio is fixed, and the transaction is expected to qualify as a tax-free exchange for Howard's stockholders.

10:25 EDT JetBlue expects CASM-ex to inflect in 2H22

10:19 EDT CYNGN Inc trading resumes

10:09 EDT CYNGN Inc trading halted, volatility trading pause

10:05 EDT Romeo Power says BorgWarner to put JV ownership stake to Romeo - In a regulatory filing, Romeo Power (RMO) disclosed that on October 25, BorgWarner (BWA) delivered a written notice to the company that BorgWarner is electing to exercise a right under the companies' joint venture operating agreement, dated May 6, 2019, to put its ownership stake in the BorgWarner Romeo Power LLC joint venture to Romeo. The operating agreement, together with the intellectual property license agreement, dated May 6, 2019, govern the operations of the joint venture, which is owned 40% by Romeo and 60% by BorgWarner Ithaca LLC. The operating agreement provides BorgWarner a right to cause Romeo to purchase BorgWarner's 60% ownership stake in the joint venture, the filing noted. "Pursuant to the terms of the operating agreement, upon exercise of a party's put right, the company and BorgWarner are required to select a nationally recognized valuation firm to determine the market value of the joint venture as of the date the put is exercised using comparable company, discounted cash flow and other standard valuation methodologies used by investment banks. The price to be paid for BorgWarner's ownership stake will be 95% of the market value of such stake based upon the joint venture valuation, reflecting a 5% discount applicable because BorgWarner is exercising such put within the third year after the date the joint venture was established, as contemplated by the operating agreement. The parties will be obligated to consummate Romeo's purchase of BorgWarner's ownership stake in the joint venture within 30 days of the joint venture valuation being determined," the filing stated.

10:01 EDT JetBlue sees 'significant' unit cost reduction in 2H22 - Expecting strong continued recovery in travel demand throughout 2022 driving relief in rents and landing fees rate headwind of ~3 - 4 pts in 2H21. Says margin-accretive Northeast Alliance expected to add ~2 - 4 pts of CASM ex-Fuel pressure in 2022.

10:00 EDT TrueBlue falls -11.8% - TrueBlue is down -11.8%, or -$3.87 to $28.82.

10:00 EDT Celestica rises 10.6% - Celestica is up 10.6%, or $1.00 to $10.45.

10:00 EDT JetBlue sees corporate recovery, while delayed, continuing through 2022

09:59 EDT JetBlue sees demand improvement throughout Q4

09:59 EDT Inspira Technologies signs exclusive distribution agreement with Waas Group - Inspira Technologies (IINN) announced that it has signed an exclusive distribution agreement with Anita Tecnica S.L. (WAAS Group). WAAS Group provides services to more than 40 international companies and devices, including respiratory systems for Siemens Healthineers AG ADR (SMMNY) and Dragerwerk AG & Co. KGaA, Dragerwerk AG. The agreement has an initial term of 7 years, subject to completion of product development and regulatory approval. The parties will collaborate on the marketing and deployment of the ART device, designed to treat deteriorating respiratory failure patients, while they are awake and breathing. The ART, an early extracorporeal respiratory support system, has the potential to minimize the need for mechanical ventilation across Spain and Portugal. According to the agreement, Anita Tecnica is committed to purchase a minimum of 1040 ART devices and 35,360 disposable units for deployment at hospitals and medical centers within a seven-year period, subject to regulatory approval for the sale and marketing of the ART devices in Spain and Portugal.

09:57 EDT JetBlue sees Q4 capacity down 4%-7% vs. 4Q19 - Sees Q4 CASM ex-fuel up 14%-16% vs. 4Q19. Comments taken from Q3 earnings conference call presentation slides.

09:50 EDT Babylon Holdings Limited (Class A Stock) trading halted, volatility trading pause

09:48 EDT General Motors to install up to 40,000 Level 2 EV chargers across U.S., Canada - General Motors announced a new community charging program to install up to 40,000 Level 2 EV chargers across the U.S. and Canada, including in underserved, rural and urban communities where charger access is limited. "This initiative, which begins in 2022, is part of GM's recently announced commitment to invest nearly $750 million to expand home, workplace and public charging infrastructure through its Ultium Charge 360 ecosystem. Through the Dealer Community Charging Program, GM will give each of its dealers Ultium Chargers that can be deployed at key locations in their respective communities. These charging stations will be available to all EV customers, not just those who purchase a GM EV. Today, nearly 90 percent of the U.S. population lives within 10 miles of a GM dealership. GM is also announcing that its new line of three Ultium-branded Level 2 smart charging stations will be available to customers directly through dealerships and online to provide more home or commercial charging options and help make EV charging more widespread," the company stated.

09:47 EDT Lockheed Martin falls -8.6% - Lockheed Martin is down -8.6%, or -$32.19 to $344.14.

09:47 EDT Dana falls -12.2% - Dana is down -12.2%, or -$3.08 to $22.10.

09:47 EDT Cazoo rises 8.0% - Cazoo is up 8.0%, or 64c to $8.64.

09:45 EDT Moderna announces Swissmedic authorizes booster dose of Covid-19 vaccine - Moderna announced Swissmedic has authorized a booster dose of Spikevax, the company's vaccine against COVID-19, at the 50 microgram dose level in particularly vulnerable individuals 12 years of age and older, at least six months after completion of the primary series. Swissmedic also approved a third dose of Spikevax at the 100 microgram dose level for people with a weakened immune system at least 28 days after the second dose. "We thank Swissmedic for their review and decision. This approval is supported by clinical evidence that a 50 microgram booster dose induces a strong immune response against COVID-19. We also appreciate their approval of a third dose of Spikevax for those with weakened immune systems," said Stephane Bancel, CEO of Moderna. "We believe that mRNA vaccines are well positioned to adapt to the evolving epidemiology of SARS-CoV-2. We are grateful for the opportunity to provide individuals in Switzerland with another layer of protection."

09:41 EDT Redbox Entertainment Inc (Class A Stock) trading resumes

09:38 EDT Entain board 'strongly believes' in future prospects after DraftKings statement - Entain (GMVHF) issued the following response to DraftKings' (DKNG) no intention to bid statement: "The Board of Entain plc notes the announcement made earlier today by DraftKings that it does not intend to make an offer for Entain. As a result of the announcement, DraftKings and its concert parties are bound by the restrictions contained in Rule 2.8 of the City Code on Takeovers and Mergers. The Board strongly believes in the future prospects of Entain, underpinned by its leading market positions, world class management team and industry-leading proprietary technology. Entain has an outstanding track record of growth having delivered 23 consecutive quarters of double digit online NGR growth, representing a 3 year CAGR of 19% across 2021.Entain's management remains focused on executing its growth and sustainability strategy and on delivering the opportunities laid out in Entain's capital markets event on 12 August to treble its total addressable market to c.$160B... As a result the Board is confident in Entain's ability to continue to deliver material value for its shareholders going forward."

09:35 EDT Riley Exploration Permian Inc trading resumes

09:33 EDT Ford, AT&T partner to bring 5G to Ford F-150 Lightning production - Ford Motor Company (F) and AT&T (T) are enhancing the Rouge Electric Vehicle Center on Ford's historic Dearborn Rouge site by outfitting it with highly secure, next-generation 5G cellular connectivity to help build the new all-electric Ford F-150 Lightning pickup. Ford's private 5G network based on AT&T 5G with AT&T's Multi-Access Edge Computing technology will support production of the 2022 Ford F-150 Lightning, the first all-electric version of America's best-selling F-Series truck.

09:31 EDT Redbox Entertainment Inc (Class A Stock) trading halted, volatility trading pause

09:30 EDT Senmiao Technology signs cooperation agreement with Chengfeng - Senmiao Technology announced the signing of a new cooperation agreement with Sichuan Chengfeng Intelligent Transportation Co., Ltd., a wholly-owned subsidiary of Neijiang Chengfeng Investment Co., Ltd. Chengfeng Investment is a state-owned company focused on customized passenger transportation, taxis, online ride-hailing, and smart technology sectors. Chengfeng is a provider of construction and maintenance services for real-time GPS monitoring systems for mobile and fixed targets in Neijiang, Sichuan Province. Since 2002, Chengfeng has established cooperation relationships with various well-known companies such as China Telecom and China Mobile. According to the terms of the Agreement, Senmiao will be responsible for providing operational support services for customized passenger transportation, intercity carpooling, city express, SAAS express and technology systems involved in digital transformation, as well as providing the development, introduction and technical support for Chengfeng's taxi brand. Chengfeng will provide certifications and resources for customized passenger transportation, intercity carpooling, online ride-hailing business licenses, and will also manage communications with local government officials.

09:26 EDT MakeMyTrip extends term of share repurchase plan - MakeMyTrip said: On November 6, 2012, our Board of Directors authorized the company to purchase outstanding ordinary shares of the company. On January 22, 2016, our Board of Directors authorized the company to increase the share repurchase plan to an amount aggregating up to $150 million at a price per ordinary share not exceeding $21.50 until November 30, 2021 and on October 26, 2021, our Board of Directors authorized the company to further extend the term of this share repurchase plan until November 30, 2023. There were no repurchases pursuant to the share repurchase plan during the second quarter of fiscal 2022. As of September 30, 2021, we had remaining authority to repurchase up to approximately $136.0 million of our outstanding ordinary shares."

09:23 EDT Stratasys and Adobe in pact to allow 3D print full-color and tactile models - Stratasys (SSYS) announced a collaboration with Adobe (ADBE) that gives artists and engineers using Adobe Substance 3D Painter a workflow that allows them to easily turn digital 3D renderings into 3D-printed models using Stratasys PolyJet 3D printing technology - all without the need to employ additional software or outside processes. Items printed on Stratasys PolyJet printers directly from Adobe Substance 3D Painter (Photo: Business Wire) Adobe Substance 3D tools can be used to create renderings for applications such as games, films, fashion, architecture, product design and consumer packaged goods. When combined with 3D printing, Substance software can be used to create product prototypes and package designs that can then be translated to 3D printed objects on Stratasys PolyJet printers. "This collaboration has allowed us to see our designs for the very first time in the physical world - which is every artist's and designer's dream," said Pierre Maheut, Head of Strategic Initiatives and Partnerships, 3D and Immersive - Substance for Adobe. "And to be honest, we have gotten a little bit emotional seeing our designs come to life and in a way that is so realistic."

09:18 EDT Rapid7 to open office in Tampa, Florida - Rapid7 announced plans to expand its U.S. presence with the opening of an office in Tampa, Florida. The company will initially open its doors at Industrious, a shared workspace located at 615 Channelside Drive, Tampa, Florida, with the intention of expanding and taking up a permanent residence in 2022. The Boston-based cybersecurity company has roughly 2,000 employees, nine North American offices and 14 offices across Europe, Asia-Pacific and Australia. With the competition for top talent increasing, Rapid7 is setting its sights on the Tampa area as one of the top emerging tech cities in the U.S., with its high concentration of renowned universities and skilled military cybersecurity experts. Rapid7 is committed to continued innovation and expanding its global footprint. The opening of the Tampa office will initially add more than 100 roles focused on data and software engineering, development, customer support, IT, and human resources, with continued growth expected over the coming years.

09:17 EDT Verb Technology announces availability of verbLIT for viewing - Verb Technology announced that its first technology symposium, verbLIT, held on October 7, 2021, is now available for viewing. verbLIT gives clients, consumers, and investors the chance to experience VERB's core shoppable video technology. The symposium showcases recently released innovations from VERB, the people behind the products, the reasons these products were developed, the experiences of clients using them, and provides a sneak peek at what else is coming.

09:16 EDT American International Holdings' EPIQ MD launches EPIQ LUX program - American International Holdings announced that its subsidiary EPIQ MD has launched its EPIQ LUX discount program, an add-on feature for its EPIQ MD members that aims to integrate highly sought-after amenities into its primary suite of telehealth services. The Epiq LUX add-on feature is available to any of Epiq MD's Premier Service Plans for an additional $9.95 per month and provides discounts for a suite of ancillary healthcare related services.

09:13 EDT Castor Maritime announces delivery of M/V Magin Phoenix, new charter agreements - Castor Maritime announces that on October 26, 2021, it took delivery of M/V Magic Phoenix, the 2008 Japanese-built Panamax dry bulk carrier it had agreed to acquire as previously announced on August 26, 2021. The vessel acquisition was financed in its entirety with cash on hand. M/V Magic Phoenix has been fixed on a time charter contract at a gross daily charter rate equal to 102% of the average of the Baltic Panamax Index 4TC routes. The charter is expected to commence on or around October 28, 2021, and will have a minimum duration of eleven months and a maximum duration of fourteen months at the charterer's option. The Company also announces that the M/V Magic Venus, a 2010 built Kamsarmax dry bulk carrier, has been fixed on a time charter contract at a gross daily charter rate of $38,000. The charter commenced on October 16, 2021, and has a duration of about 60 days.

09:12 EDT PHI Group announces ADE token launch - PHI Group and developing the Asia Diamond Exchange in Vietnam, is pleased to announce the launch of the ADE token in South Korea in connection with the Asia Diamond Exchange. The token is designed to optimize transparency and fair pricing to the diamond industry to provide enhanced benefits to all stakeholders. By validating transactions on a blockchain, there are no chances of counterfeiting or substandard pieces. Consumers will be able to design and purchase custom diamond jewelry and loose gemstones at significantly better prices by using the ADE tokens. The ADE tokens will be deflationary by setting aside profits to purchase and burn tokens as well as systematically continuing the buy-back of PHIL stock on an ongoing basis in the future. International investors may purchase and trade the tokens once they are listed on top exchanges such as Coinbase and Binance. The Asia Diamond Exchange is a modern bourse to be established in affiliation with the World Federation of Diamond Bourses. It will be the first-ever vital rough diamond exchange in Asia, comparable to the diamond exchanges in Antwerp and Dubai. Located in a Free-Trade Zone in Vietnam near an international airport in the new Global Multi-Commodities Center similar to the Dubai Multi-Commodities Centre, the ADE is a modern bourse to be established in affiliation with the World Federation of Diamond Bourses and fully compliant with the Kimberley attestation process. ADE membership will serve as a mark of distinction, opening doors and allowing access to those active in the diamond trade. The ADE ensures that its members will have the safety of only trading with reputable companies adhering to its compliance guidelines that are bound by a strict code of good business practices and ethics. The ADE will have exceptional facilities, providing fully equipped trading halls for its members and a complete service environment for everyone in the diamond pipeline. In addition to providing a full range of services to support members in their daily transactions, the ADE will also provide a complete line of ancillary services related to the diamond industry. Members and their guests will have convenient access to networking and a Trade Lounge, boiling and polishing, secure transportation, Kimberley Process Office, insurance and financing partners, gemological services, education and more. The ADE's tender and auction services will play an important role in the Vietnam diamond trade, matching the right goods from seller to buyer. The ADE will have the optimal infrastructure to host diamond tenders, using state of the art facilities, equipment and personnel to ensure secure, transparent tenders for the benefit of the seller and buyer.

09:10 EDT HP Inc. launches HP ENVY Inspire with HP+ - HP Inc. unveils HP ENVY Inspire with HP+. Beyond working and learning, ENVY Inspire can also help families preserve and celebrate the moments that matter most through new, first-of-its kind HP photo printing capabilities like custom two-sided printing, automatically adding date and location, and true-to-phone quality in modern sizes, like panorama and social-friendly square. Users can also choose from a wide range of templates available in the HP Smart App to make greeting cards, keepsakes, and more. Perfect for the 72% of families who plan to spend more on travel in 2022 than they have in the past five years to make up for lost time.

09:09 EDT UpHealth and Mazars are partnering to develop an integrated compliance roadmap - UpHealth and Mazars are partnering to collaboratively develop an integrated compliance roadmap for UpHealth. Mazars is a global leader in healthcare, providing the healthcare sector with advice, guidance and solutions to drive informed decisions and successful outcomes.

09:08 EDT Panini Group, WWE announce a multi-year trading card and collectible pact - The Panini Group and WWE announced a multi-year agreement that will make Panini WWE's exclusive trading card and collectible sticker partner. The landmark agreement will begin in the first quarter of 2022 and will include multiple trading card products during the first year. Panini's U.S. subsidiary, Panini America will be responsible for developing the WWE trading card products. The first product release - 2022 WWE Prizm - will coincide with the buildup surrounding WrestleMania WWE's biggest annual event, taking place on April 2 and 3 at AT&T Stadium in Dallas. WWE trading card products will be available at mass retailers including Walmart and Target, as well as hobby stores nationwide and online. "We have always been intrigued by WWE as a license partner and their fans' incredible passion," said Panini America CEO Mark Warsop. "Our entire team is looking forward to adding WWE, a truly iconic license, to our roster of exclusive partners. We have big plans for our WWE portfolio and the new heights we can help WWE trading cards and stickers reach in the collectibles arena."

09:07 EDT Aware to sponsor Disruptive Innovation theme for Mobile World Congress - Aware has announced that the company will be a sponsor for the Disruptive Innovation theme during this year's Mobile World Congress Los Angeles conference, taking place from October 26-28 in Los Angeles, California. Aware representatives will be onsite to demonstrate the benefits of incorporating biometric and digital identity technologies by mobile network operators. Additionally, as part of the Disruptive Innovation theme, Aware will spotlight how biometrics will play a key role in the registration of SIM cards to users. As customers around the world continue to get comfortable performing digital interactions, businesses must adapt their strategies to support the customer journey. In one of Mobile World Congress' panel presentations, "Disruptions in Data", Chris Koeneman, vice president of sales and marketing at Aware, will discuss the role biometric technologies will play in mobile customer interactions, and how they can both greatly improve security and convenience for users.

09:07 EDT My Size awarded contract from Dockers Turkey - MySize (MYSZ) announced that it has been awarded a contract from Dockers, Turkey, an American brand of garments and other accessories from Levi Strauss & Co. (LEVI). Levi Strauss & Co. Turkey, Dockers has decided to integrate MySize's proprietary AI-driven sizing technology solution. The successful integration of the MySizeID widget has reduced return rates for a subsidiary of the world's global leader in jeans wear.

09:06 EDT United Airlines increases flights between NYC and D.C. areas by 78% - United Airlines is making travel between New York City and Washington D.C. easier and more convenient, announcing it will launch new nearly hourly shuttle service between New York/Newark Liberty International Airport and Reagan National Airport on Oct. 31, and is adding five new flights between LaGuardia Airport and Washington Dulles Airport. In total, United will operate about 32 flights each day between the NYC and D.C. areas, a 78% increase and the most flights of any other airline.

09:04 EDT Cisco announces real-time meeting solution, Webex Hologram - At WebexOne, Cisco unveiled a preview of its next-generation hybrid work collaboration product. Webex Hologram is the industry's only real-time meeting solution that takes advantage of augmented reality headsets to combine feature rich Webex meeting functionality with immersive 3D holograms. With 64% of employees agreeing that the ability to work remotely directly affects whether they stay or leave a job, organizations will increasingly offer flexible work arrangements. Yet this poses a challenge for teams that require hands-on collaboration, such as design or training with a physical object. With Webex Hologram's holographic capabilities, participants can now interact in ways previously possible only in-person.

09:04 EDT SEI Investments acquires Finomial - SEI announced the acquisition of Finomial, an investor lifecycle management firm offering cloud-native financial technology. The technology is expected to be added to SEI's existing investor-focused platforms to further enhance automation and digitization capabilities, as well as reporting and transparency. Finomial's cloud-based technology is expected to complement SEI's existing platforms, including SEI Trade, the SEI Manager Dashboard, SEI Investor Platform and the Global Regulatory and Compliance Platform.

09:03 EDT Usio signs new ISV agreement with BoosterHub - Usio announced a partnership with BoosterHub, LLC, that will bring Usio's PayFac-in-a-Box payment solution to thousands of school booster clubs across the country. Usio's payment solution will be fully integrated into BoosterHub's cloud-based software that streamlines the management of booster clubs through easy club communication, e-commerce and point-of-sale solutions, volunteer management and other easy to use technology tools.

09:01 EDT Intertape Polymer signs 'The Climate Pledge' - Intertape Polymer Group announced its signing of "The Climate Pledge". Aligning the Company to the goals outlined in The Climate Pledge fits well with IPG's commitment to sustainability and its ongoing efforts to continually improve its processes, the communities in which it operates and ultimately, the planet we all call home. The Climate Pledge is a commitment co-founded by Amazon and Global Optimism to be net-zero carbon by 2040. "Signing on to The Climate Pledge is an important step in our sustainability journey at IPG, as we join more than 200 companies with a similar vision of net zero carbon by 2040," said Greg Yull, President and CEO of IPG. "The climate crisis is real and it is only through strong commitments and actions towards decarbonization from business, policymakers and society that will we be able to right the ship. By signing the pledge, IPG is demonstrating its commitment to play its part."

08:56 EDT Allegro MicroSystems intrdouces 3-phase gate driver for EV, hybrid cars - Allegro MicroSystems is expanding its QuietMotion product line with the introduction of the new A89307 automotive-qualified gate driver integrated circuit. Designed for battery cooling fans and HVAC systems in electric and hybrid vehicles, the A89307 offers ultra-low noise and vibration by using a Field Oriented Control, FOC, algorithm to drive continuous sinusoidal current to the load, helping automakers reduce noise and improve battery life, offering more miles per charge and lowering vehicle carbon footprints. "By design, EV and hybrid vehicles are quieter than traditional models with internal combustion engines-especially when they're stopped-and drivers are becoming increasingly sensitive to noise created by components such as cooling fans," said Steve Lutz, Product Line Director for Motor Drivers at Allegro. "The A89307's hardware-based algorithm makes it easier for designers to reduce fan noise while improving cooling performance and increasing miles per charge. That's good for drivers, and good for the environment."

08:53 EDT Diana Shipping announces approval for listing of OceanPal, revised record date - Diana Shipping announced that it has received approval, subject to official notice of issuance, for the listing of the common shares of OceanPal Inc. on the Nasdaq Capital Market under the ticker symbol "OP". As the Company previously announced on October 19, 2021, the Company will effect a spin-off of 100% of the common shares of its wholly-owned subsidiary, OceanPal Inc., to Diana Shipping Inc.'s existing shareholders as of the record date set forth herein. OceanPal Inc. will act as the holding company for three of the Company's older dry bulk vessels.The Company is also announcing that the previously announced record date of the OceanPal Inc. spin-off and the payment of a cash dividend in the amount of $0.10 per Diana Shipping Inc. common share has been changed to November 3, 2021. The Company expects to complete the distribution of the OceanPal Inc. common shares at a ratio of one OceanPal Inc. share for every 10 shares of Diana Shipping Inc. held on the Record Date on or around November 9, 202. To the extent the distribution would result in any shareholder owning a fractional share of OceanPal Inc. such fractional share will be rounded up to the next whole number of shares. The payment date of the cash dividend will be November 10, 2021. The ex-dividend date for the cash dividend will be November 2, 2021. With respect to the spin-off, shares of Diana Shipping Inc. will trade with due bills from the Record Date through and including the Payment Date. Accordingly, shareholders of Diana Shipping Inc. as of the Record Date must continuously hold such Diana Shipping Inc. common shares through and including the Payment Date in order to receive shares of OceanPal Inc. in the spin-off.

08:52 EDT Conduent selected by Washington HCA to advance MMIS transformation - Conduent announced a new eight-year contract with the state of Washington Health Care Authority, HCA, to implement a Pharmacy Benefit Management, PBM, module for Washington's Medicaid Management Information System, MMIS. The company's PBM module aligns with the HCA's vision for MMIS transformation and helps the agency quickly shift to next generation Software-as-a-Service technology to support its healthcare purchasing strategies and health policies. The agreement follows a series of new state laws enacted in 2020 by Washington's legislature to curb rising prescription drug costs. In addition to measures that limit consumers' out-of-pockets costs, legislators passed a first-of-its-kind law that will, in part, increase oversight of PBM business practices. "Conduent brings a deep understanding of the unique requirements to manage the fast-changing technology infrastructure that defines modular Medicaid transformation. We are thrilled to partner with the Health Care Authority to deliver well-coordinated, high value pharmacy benefit services that drive cost savings through efficiency and help improve outcomes for millions of their members," said Lydie Quebe, General Manager of Government Healthcare Solutions at Conduent.

08:52 EDT Telesat announces executive leadership appointments - Telesat, a company whose principal share holders include Loral Space & Communications (LORL), announced the appointment of industry leader Glenn Katz as Chief Commercial Officer, CCO. In addition, Tom Eaton, previously Telesat's Vice President of International Sales, is moving to the role of President of Telesat Government Solutions - a US-incorporated, wholly-owned subsidiary of Telesat. In the newly created CCO role, Katz will be responsible for product development, product management and product marketing as well as for leading and expanding Telesat's international sales team. Most recently, Katz served as Senior Vice President and General Manager of Enterprise Solutions for Comcast Business (CMCSA). After seven successful years as Telesat's Vice President of International Sales, Tom Eaton is moving to a new leadership role as President of Telesat Government Solutions. Eaton will be responsible for the group's commercial, operational and strategic activities.

08:48 EDT Paltalk upgrades rewards loyalty program for users - Paltalk announces it has successfully upgraded its rewards loyalty program for its users with the launch of Paltalk Rewards Points. Paltalk now offers more opportunities for users to earn rewards such as specialty coins, subscriptions, stickers, flair, and other popular buttons by adding 25 new reward tiers. Paltalk expects that its new internal system will incentivize valuable activity, increase revenue, and generate user engagement. Jason Katz, Chairman and Chief Executive Officer of Paltalk, commented, "Our users are terrific content creators, enriching the social experience for everyone. Our data shows that in-app rewards are an innovative tool that users regularly interact with, benefitting our shareholders, users, and the entire Paltalk ecosystem to drive engagement with loyalty and retention benefits."

08:44 EDT GE sees Industrial free cash flow stepping up in 2022 like-for-like

08:44 EDT MAG Silver appoints Jim Mallory as CSO - MAG Silver is pleased to announce that W.J. Mallory has joined the Company as Chief Sustainability Officer. Jim has more than 44 years of experience in the mining industry, in both operations and management, with his last 23 years in sustainability and executive roles for Canadian resource corporations. Jim has supported Canadian mining companies with operations in Chile, Peru, Argentina and Bolivia, and most recently several exploration and mining operations in Mexico.

08:43 EDT 180 Life Sciences publishes pre-clinical study report on CPG derivatives - 180 Life Sciences announced that its pre-clinical study report on the effects of CBG derivatives on pain, inflammation and obesity was published in the journal Molecules. Working closely with cannabinoid medicinal chemistry expert Prof. Raphael Mechoulam and team at Hebrew University in Jerusalem, and biologists at HU and Oxford University, the study describes the synthesis of three novel CBG derivative compounds and their effects in established preclinical models of pain, inflammation, and obesity. Whilst all three demonstrated robust anti-inflammatory and analgesic properties, one stood out to be of particular interest, HUM-234. HUM-234 was also shown to prevent weight gain in mice fed a high fat diet, and importantly abrogated the development of fatty liver, a condition clinically associated with multiple metabolic disorders, including diabetes and obesity and a precursor to liver fibrosis. The research set forth in the report lends further support to the growing evidence that CBG has therapeutic potential for treatment of inflammation, and as such, we believe that synthetic CBG derivatives have potential as novel drug candidates for treating several metabolic disorders which afflict ever-growing populations in the developed world.

08:41 EDT Iteris awarded $1.46M in multi-year task orders from FHWA - Iteris announced that it has been awarded multi-year task orders totaling $1.46M from the Federal Highway Administration, or FHWA, to provide the continued development, delivery and update of design for a National Highway Institute, or NHI, training and workforce development program. With the new task order agreements, which are part of an indefinite delivery/indefinite quantity, or IDIQ, contract with a ceiling of $9M, Iteris will develop, update and deliver training, supplemental materials and services to support training to advance the state of practice, and implement best practices in the areas of FHWA operations, intelligent transportation systems, or ITS, engineering, transportation cybersecurity, freight transportation logistics, travel demand and pedestrian facility design. Iteris' workforce development and training consulting services will be delivered through in-class and online or remote workshops and training, and technical assistance.

08:41 EDT Sterling Construction awarded $152M in specialty services projects in Q3 - Sterling Construction announced that its Specialty Services segment was awarded projects totaling $152M during the third quarter of 2021. These projects included data centers, ecommerce, distribution centers, industrial warehouses, and multi-family residential facilities. "We continue to see very strong end-market demand in this segment especially around E-Infrastructure which includes large data and distribution centers. In addition to our core E-Infrastructure customers, we began adding new large customers in the quarter that are expanding their Ecommerce efforts. These large-scale projects demand high-speed, high-quality execution, which enables us to differentiate ourselves from others," stated Joe Cutillo, Sterling's CEO. "These new wins in the quarter will enable us to finish 2021 strong and have a robust start to 2022."

08:40 EDT Five Below raises $1.5M for St. Jude Children's Research Hospital - Five Below announced that the Company has raised nearly $1.5 million during its recent fundraising campaign for St. Jude Children's Research Hospital and the important research and treatment it provides. Thanks to the generosity of its incredible customers, since first partnering with St. Jude in 2008, Five Below has raised more than $8.9 million for the hospital.

08:38 EDT Anicom and Cleveland Clinic begins dosing patients in breast cancer study - Anixa Biosciences announced that, in conjunction with its partner, Cleveland Clinic, it has commenced dosing of patients for a novel study of its vaccine that is being investigated for preventing triple-negative breast cancer, the most aggressive and lethal form of the disease. Anixa has a worldwide, exclusive license to the vaccine technology originating from Cleveland Clinic. Founded by the U.S. Department of Defense, the new study is a multiple-ascending dose Phase 1 trial to determine the maximum tolerated dose of the vaccine in patients with early-stage, triple-negative breast cancer as well as monitor immune response. The study will be conducted at Cleveland Clinic and will consist of 18 to 24 patients who have completed treatment for early-stage, triple-negative breast cancer within the past three years and are currently tumor-free but at high risk for recurrence. During the course of the study, participants will receive three vaccinations, each two weeks apart, and will be closely monitored for side effects and immune response. The study is estimated to be completed in the Q3 of FY22.

08:38 EDT Revive Therapeutics says DSMB supports continuing Phase 3 trial of bucillamine - Revive Therapeutics is pleased to provide an update on the Company's U.S. Food & Drug Administration Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data at each interim analysis timepoint, in which the final interim analysis will be at 800 completed patients, are only made available to the Independent Data and Safety Monitoring Board for review and recommendations on continuation, stopping or changes to the conduct of the Study. The DSMB supported continuation of the Study in its last meeting as there was no serious adverse events or safety concerns reported and it is expected that the final interim analysis meeting, which will take place at 800 completed patients to be held in Q4-2021. In light of the spread of the Delta variant of COVID-19 and as a follow on to a recent study, titled "Thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor and inhibit SARS-CoV-2 cell entry" showing that thiol-based drugs, like Bucillamine, decrease the binding of SARS-CoV-2 spike protein to its receptor, decrease the entry efficiency of SARS-CoV-2 spike pseudotyped virus, and inhibit SARS-CoV-2 live virus infection, the Company supported research under its sponsored agreement with the University of California, San Francisco in the laboratory of Dr. John Fahy to explore the utility of thiol-based drugs, including Bucillamine, against the Delta variant of COVID-19. Research results will be made available via a publication shortly. As a result of the research and the rise of the Delta variant of COVID-19, the Company has also decided to incorporate viral load testing to complement the Study to a minimum of 300 patients that will be enrolled in the Study. The viral load will allow the Company to quantify the speed in which Bucillamine can reduce viral infection of patients throughout the course of treatment, thus allowing to understand the most optimal time to introduce Bucillamine in the treatment course and provide confidence in the potential utility and effectiveness of Bucillamine in COVID-19. The Company currently has engaged a total of 46 clinical sites in fourteen states including: Alabama, Arkansas, California, Florida, Georgia, Illinois, Michigan, Nevada, New York, North Carolina, Ohio, South Carolina, Tennessee and Texas. Also one clinical site in Puerto Rico. The Company expects to eventually file an Emergency Use Authorization with the FDA in the event that the blinded results provide evidence to the DSMB's final review to recommend to pursue EUA for Bucillamine to treat mild to moderate COVID-19. In addition, the Company is in discussions with its manufacturing partner to secure commercial supply of at least 5 billion Bucillamine tablets to potentially treat at least 50 million people globally for 2022. The Company is continuing discussions with reputable international pharmaceutical companies seeking to obtain commercial rights to Bucillamine as a treatment for COVID-19 in various countries in Europe, India and Asia. In light of these discussions, Revive is pursuing a commercialization plan that would leverage the clinical results from the U.S. Phase 3 study to allow for drug approvals globally.

08:37 EDT AGM Group Holdings and Meten Edtechx announces strategic partnership - AGM Group Holdings (AGMH) announced it has entered into a strategic partnership with Meten Holding Group (METX). The partnership will primarily focus on research and development support for blockchain applications, and in establishing a supply chain for cryptocurrency mining. The agreement includes an initial order from Meten for 1,500 Bitcoin mining machines worth $12M Meten also has an option to purchase additional machines. AGMH through its strategic partnership with HighSharp Electronic Technology has built a cutting-edge R&D capability with engineers who are experts in blockchain and related technologies, which is also the major reason why Meten chose to partner with AGMH.

08:36 EDT Akoya Biosciences appoints Pascal Bamford as SVP, R&D, Laboratory Operations - Akoya Biosciences (AKYA) announced the appointment of Pascal Bamford, PhD, as Senior Vice President,, or SVP, Research and Development, or R&D, and Laboratory Operations. Dr. Bamford joins Akoya with scientific and operational experience, leading teams in developing and implementing products and shepherding them through international regulatory agencies to reach customers and patients worldwide. Most recently, as Senior Vice President of Products and Services Research and Development at Exact Sciences (EXAS), Dr. Bamford had a role in driving the growth of the company's genomic clinical testing business.

08:35 EDT Avid Bioservices to join S&P SmallCap 600 Index - Avid Bioservices announced that the company will be added to the S&P SmallCap 600 Index, effective prior to the open of trading on Friday, October 29, 2021.

08:34 EDT NetSol Technologies announces expansion of partnership with CGI in Europe - NETSOL Technologies (NTWK) announced an expansion of its strategic partnership with leading IT and business consulting services firm CGI (GIB) in Europe. The agreement builds on the close collaboration between the two global IT service providers in the United Kingdom and the United States. The two companies have teamed up to offer NETSOL's premier, next-generation NFS Ascent(R) platform to the global finance and leasing industry, supported by CGI's local business consulting, IT integration, and managed service solutions. As part of its expanded relationship with NETSOL, CGI will integrate NFS Ascent within its clients' complex IT and operating environments and ensure the solution is configured to meet local market practices and finance, risk and regulatory compliance policies. "Partnering with a global IT service provider like CGI enables us to provide our customers with leading industry and application-specific IT solutions," said Najeeb Ghauri, Founder, Chairman and Chief Executive Officer of NETSOL Technologies. "This important and expanded partnership will be most impactful to our joint customers in the commercial, finance and leasing sectors. With CGI's expertise, we expect to accelerate and maximize the value proposition from IT investments and deliver the results our customers need to streamline and grow their businesses."

08:33 EDT Osisko Development announces drilling results from Cariboo project - Osisko Development announced drilling results from the 2021 exploration and category conversion drill program campaign at its Cariboo Gold Project in central British Columbia. Summary: A total of 152,000 meters were drilled in 2021, of which 28,000 meters and 92 holes were drilled at Lowhee Zone on Barkerville Mountain. Recent assay results include holes BM-21-037 to BM-21-051. BM-21-047 intersected a mineralized vein corridor from 121.00 meters to 128.75 meters core depth and assayed 158.40 g/t Au over 7.75 meters including a sample with visible gold that assayed 2,420.00 g/t Au over 0.50 meter. BM-21-049, located 130 meters along strike from BM-21-047, returned assays of 19.03 g/t Au over 15.20 meters including a sample of 482.00 g/t Au over 0.50 meter. Other samples over 100.00 g/t Au include 157.50 g/t Au over 0.50 meter in hole BM-21-039 and 103.50 g/t Au over 1.00 meter in hole BM-21-046. Assay Highlights: 6.77 g/t Au over 9.05 meters in hole BM-21-037 including 70.40 g/t Au over 0.70 meter; 26.80 g/t Au over 0.55 meter in hole BM-21-038; 157.50 g/t Au over 0.50 meter in hole BM-21-039; 16.46 g/t Au over 7.15 meters in hole BM-21-046 including 103.50 g/t Au over 1.00 meter; 158.40 g/t Au over 7.75 meters in hole BM-21-047 including 2,420.00 g/t Au over 0.50 meter; 27.60 g/t Au over 0.80 meter in hole BM-21-047; 38.70 g/t Au over 0.60 meter in hole BM-21-048; 9.81 g/t Au over 3.50 meters in hole BM-21-049 including 60.30 g/t Au over 0.50 meter; 19.03 g/t Au over 15.20 meters in hole BM-21-049 including 482.00 g/t Au over 0.50 meter; 29.70 g/t Au over 0.50 meter in hole BM-21-051; 42.70 g/t Au over 0.55 meter in hole BM-21-051; 32.20 g/t Au over 0.70 meter in hole BM-21-051. Vein corridors are defined as a high-density network of mineralized quartz veins within the axis of the last folding event and hosted within a brittle meta-sandstone or calcareous meta-sandstone. Vein corridors are modelled at a minimum thickness of 2 meters and average about 4.5 meters true width. Individual mineralized veins within these corridors have widths varying from centimeters to several meters and strike lengths from a few meters to over 50 meters. These corridors have been defined from surface to a vertical depth averaging 300 meters and remain open for expansion at depth and along strike. Gold grades are intimately associated with quartz vein-hosted pyrite as well as pyritic, intensely silicified wall rock haloes in close proximity to the veins. True widths are estimated to be 60% to 75% of reported core length intervals. Intervals not recovered by drilling were assigned zero grade.

08:29 EDT Ensysce Biosciences appoints Linda Pestano as CDO - Ensysce Biosciences has appointed Linda Pestano, PhD, Chief Development Officer effective October 15, 2021. Pestano has worked through her career to guide the development of novel therapeutics to improve patient outcomes and quality of life. Dr. Pestano received her PhD from Tuffs University and undertook a Post-Doctoral Fellowship with Dana Farber Cancer Institute at the Harvard Medical School in Boston.

08:28 EDT Asia Pacific Wire & Cable Corp to host 2021 annual shareholders meeting - Asia Pacific Wire & Cable Corporationannounced that the Company will host its 2021 Annual General Meeting for shareholders at its headquarters located at Room B, 15th Floor, No. 77, Dunhua South Road, Section 2, Taipei, 106, Taiwan on Thursday, December 23, 2021 at 9 am EDT. The Meeting is being held for the purposes below, and additional information, including the agenda of all matters being put to a vote of shareholders, will be provided in the Notice of Meeting and related proxy statement that will be provided to shareholders. As of the date hereof, the agenda is intended to include for voting by shareholders the matters set forth below. The Company reserves the right to finalize the meeting agenda in its discretion. To approve the written record of the last Annual General Meeting of Shareholders of the Company held on September 18, 2020 To approve the minimum number of directorships at two and the maximum number of directorships at ninTo elect up to nine directors To approve the compensation to be paid to each of the directors To present before the Meeting the audited financial statements of the Company for the fiscal year ended December 31, 2020 To approve the appointment of PricewaterhouseCoopers Taiwan as the independent auditor of the Company for the 2021 fiscal year, and to authorize the Board of Directors of the Company acting through its Audit Committee to determine the remuneration of the independent auditors for the 2021 fiscal year To consider such other matters as may be appropriately brought before the shareholders The record date for shareholders wishing to vote in the Meeting is planned to be set as November 5, 2021. All shareholders of record as of the record date shall be entitled to one vote per share on all matters put to shareholders at the Meeting, all as shall be more fully described in the Notice of Meeting and related proxy statement that will be provided to shareholders of record.

08:25 EDT authID.ai, HRB announce deployment of biometric identity services - authID.ai announced that Hamilton Reserve Bank, HRB, a fully regulated global bank with worldwide offices, has deployed authID.ai's Identity as a Service, IDaaS, platform. HRB has deployed Verified, authID.ai's biometric multi-factor cloud-based authentication product that offers the ease of a "selfie" to confirm identity, thereby eliminating the use of vulnerable one-time passwords and knowledge-based questions for securing transactions and account recovery. As HRB launches new digital banking services with the Temenos Infinity banking platform, authID.ai, a Temenos Marketplace provider, provides high levels of identity assurance to HRB and its expanding international clientele. authID.ai's biometric identity products are helping HRB reduce operational costs associated with supporting password resets, and mitigate security risks arising from stolen passwords, phishing, and account takeovers. In addition to deploying Verified, Proof by authID.ai delivers automated identity verification during digital onboarding of HRB's global clientele, including quick mobile identity document capture and authentication, liveness confirmation, and facial biometric matching of a selfie to the credential photo. "Everything starts with trusted identity," said Tom Thimot, CEO of authID.ai. "Our identity platform offers innovative solutions that are flexible, fast, and easy to integrate. authID.ai is committed to helping banks across the globe reduce the risk of identity fraud, eliminate the costs and hassles of passwords and ultimately deliver seamless authentication experiences to their customers."

08:22 EDT Kratos Defense awarded new US Air Force program of $17.6M - Kratos Defense & Security Solutions, a leading National Security Solutions provider, announced that Kratos Unmanned Systems Division, KUSD, has been awarded a $17,677,612, 12-month cost plus fixed-fee contract to design and develop an Off Board Sensing Station, or OBSS, Unmanned Aerial System in support of Air Force Research Laboratory's Autonomous Collaborative Platforms technology maturation portfolio. Work under the program award will be performed at secure Kratos engineering and technology facilities located in Texas, California, and Oklahoma over the next 12 months. The OBSS program includes an optional subsequent 15-month Manufacture and Demonstration period. With the base and option awards, total contract to Kratos would be $49M. The OBSS vehicle is intended to be an affordable, highly modular conventional takeoff and landing jet-powered UAS. The Kratos OBSS solution incorporates manufacturing techniques that enhance its ability to not only provide significant performance for sensor extension missions for manned jet aircraft, but also will accommodate significant offensive weapons volume to also act as a weapons bay extension for manned aircraft. Eric DeMarco, President and CEO of Kratos Defense and Security Solutions, said, "Kratos is committed to disrupting the government contractor national security market by providing rapid, agile, affordable, and relevant systems to our defense customers. The recent selection of Kratos to develop next-generation OBSS aircraft for our partner, the U.S. Air Force, re-affirms our approach to treat affordability as a technology. Kratos Ghost Works, which played a significant role in the design of our OBSS system, has once again demonstrated that our real, proven, digital engineering process, methodology, assets, and infrastructure are optimized for affordable system development. At Kratos, we develop products, not just PowerPoint presentations, and we will continue to pursue affordable, innovative solutions to support our USAF customer in the current challenging budgetary environment."

08:20 EDT Motus GI Holdings announces presentation of results on Pure-Vu System - Motus GI announced that results from an independent single-center study of the Pure-Vu System as an adjunct to colon cleansing in patients with inadequate bowel preparation, IBP, were featured in a presentation at the 2021 American College of Gastroenterology, ACG, Annual Scientific Meeting. "We are excited to see the positive results of this real-world, independent study of the Pure-Vu System supporting both inpatient and outpatient procedures for screening and emergency colonoscopies at the ACG meeting. While we have conducted extensive research of the Pure-Vu System around inpatient screening colonoscopies following bowel preparation, this evaluation of the Pure-Vu System included three patient cases where the Pure-Vu System was successfully used in emergency colonoscopy without bowel preparation. We believe there is tremendous potential for the Pure-Vu System to support colonoscopies following limited bowel preparation, which supports results from other studies," commented Tim Moran, Director and Chief Executive Officer at Motus GI. In the study, the Pure-Vu was used in 40 patients with IBP to complete the colonoscopy. The indication for colonoscopy was either diagnostic or colorectal cancer screening/surveillance. Pure-Vu was used as an adjunct to IBP to allow completion of procedure in 37 patients. In patients with IBP, the mean BBPS score improved from 3.1 to 8.5 after intra-procedural cleansing. Three patients had active lower gastrointestinal bleeding , and Pure-Vu was used without bowel preparation to promptly detect the etiology and possibly treat. When used in emergency colonoscopy without bowel preparation, procedures could be completed in all three patients detecting and treating diverticular and post-polypectomy bleeding in one patient each and diagnosing severe right sided ischemic colitis in another. Use of Pure-Vu did not interfere with the performance of endoscopic interventions including biopsy, cold/hot snare polypectomy, or EMR. Besides minor mucosal trauma in two cases, no major complications were observed with Pure-Vu.

08:18 EDT Gain Therapeutics announces formation, appointments to SAB - Gain Therapeutics announced the formation of its Scientific Advisory Board, SAB. Luca Benatti, Ph.D. will serve as chair of the SAB. Additional appointments include Samuel Broder, M.D.; Lorenzo Leoni, Ph.D.; Joanne Taylor, Ph.D.; and Michel Vellard, Ph.D. Benatti will lead Gain's SAB and work closely with the company's leadership team to shape the scientific strategy and advance Gain's early-stage programs. Benatti serves as the Chief Executive Officer and a Director of EryDel S.p.A., a private biotechnology company focused on rare diseases. Broder has been at the forefront of science and medicine in many diverse arenas throughout his career. He is the former Director of the National Cancer Institute. Leoni is a co-founder of Gain Therapeutics and currently serves as Chairman of the Board of Industrie Biomediche Insubri SA, a board member of Artificaly SA, and a managing partner of TiVenture SA. Taylor has over 25 years experience in the neuroscience industry. She served as vice president for Prescient Healthcare Group. Vellard currently serves as chief scientific officer for Home Biosciences.

08:16 EDT ADMA Biologics CEO buys 350K shares, CFO buys 30K shares of common stock - In regulatory filings, ADMA Biologics disclosed that its CEO Adam Grossman bought 350K shares of common stock forr $350K while CFO Brian Lenz bought 30K shares for $30K on October 25th.

08:14 EDT Verizon, Project Kuiper partner to develop connectivity solutions - Verizon Communications Inc. (VZ) and Project Kuiper, an advanced low Earth orbit satellite network from Amazon.com, Inc. (AMZN), announced a strategic collaboration to develop connectivity solutions for unserved and underserved communities. As part of the collaboration, Project Kuiper and Verizon have begun to develop technical specifications and define preliminary commercial models for a range of connectivity services for U.S. consumers and global enterprise customers operating in rural and remote locations around the world. Project Kuiper is an initiative to increase global broadband access through a constellation of 3,236 satellites in low Earth orbit around the planet. The system will serve individual households, as well as schools, hospitals, businesses and other organizations operating in places where internet access is limited or unavailable. Amazon has committed an initial $10 billion to the program, which will deliver fast, affordable broadband to customers and communities around the world.

08:13 EDT VYNE Therapeutics announces preclinical data on VYN201 - VYNE Therapeutics announced preclinical data showing that its pan-bromodomain and extra-terminal, BET, inhibitor, VYN201, significantly reduced the expression of several key pro-inflammatory cytokines relevant to Th17-mediated autoimmune diseases in an animal model and an ex vivo human tissue study. The pathogenesis of many autoimmune diseases is linked to the proliferation and activity of Th17 cells, which include several diseases that VYNE is evaluating for its VYN201 program. "We are encouraged by the evolving therapeutic profile of our lead topical BET inhibitor, VYN201," said David Domzalski, VYNE's Chief Executive Officer. "In collaboration with our newly formed scientific advisory board, we look forward to presenting additional VYN201 data as we continue to advance this promising and highly differentiated product candidate across our immuno-inflammatory development programs." Preclinical Model of Th17 Inflammation. VYNE's proprietary formulation of VYN201 was evaluated in a preclinical model in which dorsal depilated mice are topically dosed with imiquimod cream to induce a Th17 inflammation pathology over a 7-day induction phase. A further 7-day treatment phase evaluated three doses of VYN201 compared to a class 1 super-potent glucocorticosteroid product positive control and vehicle control. Further, an imiquimod-naive control group was included for VYN201 vehicle treatment. Key findings from the study: A dose-dependent improvement in the signs and symptoms of inflammation was observed for VYN201 treatment groups; Treatment with VYN201 0.1% resulted in a 94% reduction in the composite inflammation severity score of erythema and scaling, relative to the vehicle control group at treatment day 7; Animals treated with VYN201 0.1% experienced a reduction in inflammation comparable to those treated with the class 1 super-potent glucocorticosteroid clobetasol propionate 0.05% cream. Corresponding dose-dependent reductions were observed across all treatment groups in Th17-relevant cytokine biomarkers of inflammation, including IL-1beta, IL-17, IL-6, IL-36 and TNFalpha for VYN201-treated animals. Treatment with VYN201 at all concentrations appeared well-tolerated based on the following observations: Animals treated with VYN201 continued to gain body weight in a similar manner to the healthy control group, whereas animals treated with clobetasol propionate cream 0.05% had a mean body weight loss of approximately 17% compared to the animals treated with VYN201 0.1%. Animals treated with VYN201 had no evidence of dermal tolerance issues, consistent with the healthy control group. Ex-vivo Anti-inflammatory Effect on Human Skin Tissue Compared to Ruxolitinib: An ex vivo human skin tissue study was also conducted. Human skin biopsy tissue was stimulated to induce a Th17 immuno-phenotype using a method derived from Feghali-Bostwick et al. In the study, the release of several key pro-inflammatory cytokines were substantially reduced when Th17-stimulated human skin tissue was treated with VYN201, resulting in greater than 95% inhibition of IL-17, IL-36 and CXCL10 release relative to vehicle control. VYN201 also demonstrated a superior anti-inflammatory effect on these cytokines when compared to the JAK1/2 inhibitor, ruxolitinib, at identical concentrations.

08:13 EDT Energy Recovery wins over $21.9M in contracts for SWRO plants in Saudi Arabia - Energy Recovery announced contract awards totaling more than $21.9M for its PX Pressure Exchanger energy recovery devices and related equipment and services for seawater reverse osmosis desalination, SWRO, plants in the Kingdom of Saudi Arabia. The orders are expected to ship through Q2 of 2022, and the plants will be able to produce a combined total over one million cubic meters of water per day or m3/day. Energy Recovery Wins Contracts Totaling over $21.9 Million for SWRO Plants in Kingdom ofSWRO Plants in Kingdom of .Saudi Arabia.

08:12 EDT Everi Holdings announces five-year agreement with Delaware Lottery - Everi Holdings announced a five-year agreement with the Delaware Lottery to launch the Company's high-performing gaming content. Everi will bring an extensive library of its games to Delaware for the first time with an anticipated late 2021 launch at three properties. The company plans to install nearly 500 units across Casino at Delaware Park, Dover Downs Hotel & Casino, and Harrington Raceway & Casino by early 2022.

08:12 EDT BioNTech to initiate construction of mRNA vaccine facility in Africa in mid-2022 - BioNTech announced that the Company plans to initiate the construction of the first state-of-the-art manufacturing site for mRNA-based vaccines in the African Union in mid-2022. This is the next step in BioNTech's efforts to implement sustainable end-to-end vaccine supply solutions on the African continent. The decision is the result of a meeting between Rwanda's Minister of Health, Dr Daniel M. Ngamije, Senegal's Minister of Foreign Affairs Aissata Tall Sall, Ugur Sahin, M.D.,CEO and Co-Founder of BioNTech and Sierk Poetting, COO of BioNTech as well as Dr Sabin Nsanzimana, Director-General of Rwanda Biomedical Centre and Dr Amadou Alpha Sall, Directeur-General of Institut Pasteur de Dakar in Kigali, Rwanda. The meeting occurred upon the invitation of the kENUP Foundation and took place as a side-event of the Second Ministerial Meeting of the African Union and the European Union and resulted in a Memorandum of Understanding. This comes after the parties signed a Joint Communique at a previous meeting in Berlin on August 27, 2021. The parties agree to jointly establish end-to-end manufacturing capacities for mRNA-based vaccines in Africa starting immediately. BioNTech has finalized the construction plans and ordered the assets, which will be delivered by mid-2022. The new manufacturing facility could become the first node in a decentralized and robust African end-to-end manufacturing network enabling an annual manufacturing capacity of several hundreds of million mRNA vaccine doses. BioNTech plans to develop and implement a scalable construction network based on the expertise and learnings from the ramp-up of the Company's production facility in Marburg. To enable an expedient set-up of production capacities according to GMP standards, BioNTech will start with the construction and validation of a first production line enabling the manufacturing of drug product for about 50 million of e.g. COVID-19 vaccine doses per year, once fully operational. The capacity will be increased sequentially by adding further manufacturing lines and sites to the manufacturing network on the continent, supporting the production of several hundreds of millions of mRNA vaccine doses. BioNTech will initially staff, own and operate the facility to support the safe and rapid initiation of the production of mRNA-based vaccine doses. BioNTech plans to transfer manufacturing capacities and the know-how to local partners. Therefore, BioNTech, the Rwanda Development Board and Institut Pasteur de Dakar in Senegal agreed to swiftly build-up the required human resources capacity and systems so that the partners can take over ownership and operational duties. In parallel, the Republic of Rwanda and the Institut Pasteur de Dakar have committed themselves to scale-up fill and finish capacities to complete the local end-to-end manufacturing process. In addition, BioNTech is in discussions about an expansion of the current partnership with Cape Town-based vaccine manufacturer Biovac, which is part of the Pfizer-BioNTech COVID-19 vaccine manufaturing network.

08:11 EDT I-Mab announces partnership with Sinopharm - I-Mab announced that the company has entered into a strategic partnership with Sinopharm Group to strengthen its commercial capabilities and accelerate its commercialization transformation. I-Mab will authorize more than 300 of Sinopharm's subsidiaries as distributors across China to support distribution and retail allocation to terminal markets while the company leads the overall commercial activities. The partnership will also include alliance on key projects, to jointly accelerate the commercialization and go-to-market process of I-Mab's differentiated and novel products to meet the urgent unmet medical needs of the large population of Chinese patients. The company is rapidly advancing clinical development of its innovative and globally competitive late-stage assets. Felzartamab, a differentiated anti-CD38 antibody, is expected to be the first drug brought to the Chinese market by I-Mab, which is on track to submit BLA for third-line multiple myeloma treatment later this year. In addition, I-Mab has completed patient enrollment in a phase 3 registrational trial of felzartamab in combination with lenalidomide as a second-line therapy in patients with multiple myeloma.

08:10 EDT Vyant Bio announces Robert Fremeau as Chief Scientific Officer - Vyant Bio (VYNT) announced the appointment of Robert Fremeau Jr., Ph.D., as Chief Scientific Officer. Dr. Fremeau is an experienced R&D leader with over two decades of drug discovery experience. As a Scientific Director at Amgen (AMGN), he led and contributed to multiple teams that advanced small molecules into clinical trials against innovative targets across neurological indications.

08:10 EDT Otonomo Technologies launches Otonomo app on Salesforce AppExchange - Otonomo Technologies (OTMO) announced it has launched the Otonomo App on Salesforce AppExchange (CRM), empowering customers to easily access rich vehicle data within their Salesforce Sales Cloud and Service Cloud. By having customer and connected vehicle data in one place, dealerships, leasing operations, fleets, roadside assistance providers, insurers and others can gain deeper insights, create new business opportunities and optimize operations.

08:09 EDT GE: Aviation results reflect significant improvement in NT market fundamentals - CEO Culp says departure trends are better than the August dip and have recovered to down 23% of 2019 levels. The executive sees the acceleration in traffic continuing as travel restrictions lift and vaccination rates increase.

08:09 EDT Baker Hughes in pact with machine health solution firm Augury - Baker Hughes has announced an investment in and a multi-year commercial alliance with Augury, a machine health solution provider, to deliver an expanded set of asset performance capabilities, providing connected data, analytics and insights into energy and industrial assets. The alliance builds on Baker Hughes' existing asset performance management capabilities and domain expertise in critical industrial assets. Through the alliance, customers will now benefit from end-to-end visibility into the health and performance of their critical assets to balance of plant machines, resulting in reduced downtime, increased availability, and lower maintenance costs. Extending Baker Hughes' APM solutions with Augury's machine health capabilities will also be important to Baker Hughes' efforts to accelerate digital transformation and decarbonization in the energy and industrial sectors.

08:07 EDT GE CEO: Results reflect significant improvement in near-term market fundamentals - Comments taken from Q3 earnings conference call.

08:06 EDT Lightning eMotors announces increase in orders, reorders from CalACT - Lightning eMotors announced an increase in orders, and reorders from the CalACT Vehicle Purchasing Cooperative managed by Morongo Basin Transit Authority, or MBTA. The increase in orders are from public agencies who are members of the California Association for Coordinated Transportation, or CalACT. Lightning eMotors has delivered eight of 11 vehicles initially ordered and expects to deliver the remaining three before the end of the year. An additional five orders from more new agencies are also on track to close in the coming month.

08:05 EDT Microsoft expanda global payments relationship with Worldpay from FIS - Microsoft (MSFT), has expanded its global payments relationship with Worldpay from FIS (FIS). Worldpay will provide online credit and debit card processing for Microsoft online store fronts including, Xbox, Microsoft Advertising, Microsoft Azure and other Microsoft brands in the Americas, Europe and Asia Pacific. "Microsoft has been working with Worldpay in Latin America since 2014, and the expanded relationship will see Worldpay process online payments for the company globally. In addition to payment processing, Microsoft will make use of value-added services from Worldpay including Account Updater, which is meant to automatically ensure subscriber-based payment card credentials are always up to date for a seamless customer experience, as well as solutions designed to enhance authorization rates and tokenized security," added the company in a statement.

08:02 EDT Lockheed Martin sees FY22 CapEx $2B, independent R&D $1.5B - Sees FY22 dividend payments $3B. Sees up to $6B in share repurchases over the next 12-18 months.

07:58 EDT Lockheed Martin sees FY21 segment operating profit $7.35B - Prior view was $7.38B-$7.52B. Sees FY21 net FAS/CAS pension adj. of $665M vs. prior $655M outlook. Comments taken from Q3 earnings conference call presentation slides.

07:52 EDT DraftKings 'will not make firm offer' for Entain - DraftKings (DKNG) confirms that, following further analysis and discussions with the Entain board of directors, it will not make a firm offer for Entain (GMVHF). Commenting on this, Jason Robins DraftKings CEO, Co-Founder and Chairman of the Board said: "After several discussions with Entain leadership, DraftKings has decided that it will not make a firm offer for Entain at this time. Based on our vertically-integrated technology stack, best-in-class product and technology capabilities and leading brand, we are highly confident in our ability to maintain a leadership position and achieve our long-term growth plans in the rapidly growing North America market." As a result of this announcement, DraftKings is bound by the restrictions under Rule 2.8 of the Code for six months following the date of this announcement. For the purpose of Rule 2.8 of the Code, DraftKings reserves the right to set aside the above statement and the restrictions in Rule 2.8 of the Code in the following circumstances: with the agreement of the board of directors of Entain; following the announcement of a firm intention to make an offer for Entain by or on behalf of a third party; following the announcement by Entain of a "whitewash" proposal or a reverse takeover; or where the Takeover Panel has determined that there has been a material change of circumstances.

07:45 EDT Vasta enters distribution agreement for Mackenzie Learning System - Vasta Platform announces that it has executed on October 25, 2021, through its wholly-owned subsidiary Somos Sistemas de Ensino S.A., a distribution agreement with Instituto Presbiteriano Mackenzie, pursuant to which Vasta will be the sole and exclusive distributor of the Mackenzie Learning System across all of the basic education segments in Brazil that it serves. The Mackenzie Learning System is a Christian confessional education system with strong roots in Brazil. Pursuant to the distribution agreement, Mackenzie shall remain responsible for the development of the didactic and learning materials of the Mackenzie Learning System and the definition of the pedagogy and methodology. Vasta shall be responsible for pedagogic services, technological products and all services relating to the commercialization and expansion of the Mackenzie Learning System brand. The Agreement will start in 2022, in a long-term basis.

07:41 EDT Tilray selected by Luxembourg Ministry of Health as supplier of GMP cannabis - Tilray announced it has been selected by the Luxembourg Ministry of Health as a supplier of Good Manufacturing Practice, or GMP, certified medical cannabis products for the country's medical cannabis program. Following this selection, Tilray will supply a variety of its pharmaceutical-grade medical cannabis products, including extracts and dried flower with different degrees of THC and CBD for patients with varying medical conditions. These prescription-based medical cannabis products will be administered to qualifying patients in Luxembourg under the supervision of physicians.

07:38 EDT Cybin announces FDA authorization of IND for Kernal's Flow study of ketamine - Cybin announced that the U.S. Food and Drug Administration has authorized an Investigational New Drug application to proceed with the Company's sponsored feasibility study using Kernel's Flow technology to measure ketamine's psychedelic effect on cerebral cortex hemodynamics. "The word psychedelic means 'mind-manifesting,' but what has been missing is useful 'mind-imaging'-the ability to dynamically trace the neural correlates of human conscious experience. Conventional neuroimaging just isn't dynamic enough to study the psychedelic experience in the brain as it happens. This study of ketamine's psychedelic effects while wearing headgear equipped with sensors to record brain activity could open up new frontiers of understanding," said Dr. Alex Belser, Cybin's Chief Clinical Officer. Leveraging Kernel's quantitative neuroimaging technology may lead to new frontiers in psychedelic therapeutics by enabling the acquisition of longitudinal brain activity before, during and after a psychedelic experience, providing quantification of what was previously subjective patient reporting. "Quantitatively measuring the brain within the context of a psychedelic experience is a promising frontier," said Bryan Johnson, founder and Chief Executive Officer of Kernel. "With Kernel Flow, Cybin's researchers can start putting numbers and quantification to subjective states of mind, including altered ones."

07:37 EDT Lockheed Martin sees total net FAS/CAS pension benefit of $2.2B in FY22 - The company currently expects a total net FAS/CAS pension benefit of approximately $2.2 billion in 2022, which includes total expected U.S. Government cost accounting standards pension cost of approximately $1.8 billion and total expected financial accounting standards pension income of approximately $400 million. The estimated FAS pension income amount assumes a 2.75% discount rate (the same rate used for the remeasurement of the defined benefit pension plans impacted by the pension risk transfer transaction in the third quarter of 2021), a 10.0% return on plan assets in 2021, and a 6.5% expected long-term rate of return on plan assets in future years, among other assumptions. A change of plus or minus 25 basis points to the assumed discount rate, with all other assumptions held constant, would result in an incremental increase or decrease of approximately $10 million to the estimated net 2022 FAS/CAS pension benefit. A change of plus or minus 100 basis points to the return on plan assets in 2021 only, with all other assumptions held constant, would result in an incremental increase or decrease of approximately $15 million to the estimated net 2022 FAS/CAS pension benefit. The company does not expect to make any contributions to its qualified defined benefit pension plans in 2022. The company will complete the annual remeasurement of its postretirement benefit plans and update its estimated 2022 FAS/CAS pension adjustment on Dec. 31, 2021. The final assumptions, including the discount rate and actual investment return for 2021, may differ materially from those discussed above.

07:35 EDT InMode sees FY21 non-GAAP EPS $1.91-$1.93, consensus $1.86 - Sees FY21 revenue $343M-$347M, consensus $341.03M. Sees FY21 Non-GAAP gross margin 84%-86% and Non-GAAP income from operations $165M-$167M.

07:34 EDT ContraFect to present data on potential DLAs to treat pulmonary infections in CF - ContraFect announces it will be presenting a poster on the activity of direct lytic agents, DLAs, against common Gram-negative pathogens responsible for pulmonary infections in Cystic Fibrosis, CF, patients at the North American Cystic Fibrosis Conference, which will be held virtually from November 2-5, 2021. Poster presentation at NACFC 2021: "Direct Lytic Agents, a Novel Family of Antimicrobial Agents, Exert Potent in vitro Bactericidal Activity Against Gram-negative Pathogens Which Cause Pulmonary Infections in CF Patients, Including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans."

07:32 EDT Provention Bio reports results from PROVENT study of PRV-101 - Provention Bio announced positive interim results from PROVENT, or PROtocol for coxsackievirus VaccinE in healthy voluNTeers, a first-in-human study of PRV-101, a polyvalent inactivated coxsackievirus B, or CVB, vaccine candidate targeting all five key CVB strains associated with type 1 diabetes, or T1D, autoimmunity. Provention is developing PRV-101 for the prevention of acute CVB infection and the potential delay or prevention of T1D and celiac disease. In this interim analysis, PRV-101 met the primary endpoint demonstrating that it was well tolerated in this study, with no treatment-emergent Serious Adverse Events, Adverse Events of Special Interest, or Adverse Events that led to study drug discontinuation or study withdrawal. PRV-101 also met the secondary efficacy endpoint as it induced high titers of viral-neutralizing antibodies against all CVB serotypes included in the vaccine in a dose- dependent fashion. PRV-101, licensed from Vactech Oy, is designed to prevent acute CVB infections and, in individuals at increased risk due to genetic susceptibility, to prevent CVB-triggered autoimmune damage to pancreatic beta cells that often progresses to T1D and damage to intestinal cells that may lead to celiac disease.

07:21 EDT Keep launches its healthy snacks on Missfresh platform - Mobile fitness app Keep has launched its range of healthy snacks on Missfresh's on-demand online retail platform, leveraging the neighborhood retail company's fast delivery logistics network in 17 first- and second-tier cities across China. The range comprises five products: KEEP Dark Chocolate with High Protein and Fiber, KEEP Dark Chocolate with Mengba Sugar, KEEP Daily Protein Bar, KEEP Chicken Breast with Egg White, and KEEP Vegetable Beef Pie.

07:20 EDT Bicycle Therapeutics, Genentech team to develop immuno-oncology therapies - Bicycle Therapeutics (BCYC) announced that Genentech, a member of the Roche Group (RHHBY), has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies. Bicycle and Genentech are collaborating on the discovery and pre-clinical development of novel Bicycle-based immunotherapies against multiple targets. Pursuant to the terms of the February 2020 agreement, Genentech has exercised an option to include a new program under the agreement, triggering a $10M payment to Bicycle. None of the compounds in Bicycle's wholly owned oncology pipeline, including its immuno-oncology candidates, are included in the collaboration. "We are pleased both with the progress achieved so far in our ongoing work with Genentech and that Genentech has elected to exercise an option to add a new program under the collaboration. We believe the expansion of our collaboration underscores the potential utility of Bicycles compared to other modalities, as well as the potential broad applicability of Bicycles in a wide-range of targets," said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. "We look forward to continuing to work closely with the preeminent immuno-oncology team at Genentech to develop potential new cancer treatments based on Bicycles."

07:18 EDT Else Nutrition announces date for special investors conference - ELSE NUTRITION HOLDINGS provides an update on its upcoming investors conference. Due to the COVID-19 travel and assembly restrictions in the U.S., the company will host a virtual online event for investors and shareholders on November 18th, 2021 at 11am EST. Final registration and RSVP links will be provided separately.

07:17 EDT Avrobio appoints Essra Ridha, M.D as Chief Medical Officer - Avrobio announced the appointment of Essra Ridha, M.D., MRCP, FFPM, as chief medical officer. "Dr. Ridha brings wide-ranging expertise in early- and late-stage clinical development of ex vivo lentiviral gene therapies. As vice president, clinical development at AVROBIO, she has guided the strategic and scientific development of several AVROBIO gene therapy programs.," said the company.

07:15 EDT Waste Management sees FY21 revenue growth 17% -17.5% - Total Company revenue growth in 2021 is expected to be between 17% and 17.5%. Combined internal revenue growth from yield and volume in the collection and disposal business is expected to be about 6.5%, driven by the Company's disciplined pricing programs and strong outlook for continued volume recovery. Adjusted operating EBITDA is expected to be between $5.0 billion and $5.1 billion in 2021. Free cash flow is projected to be between $2.5 billion and $2.6 billion in 2021.The Company is on target to capture between $80 million and $85 million in cost synergies in 2021 from the acquisition of Advanced Disposal, which is on track to achieve $150 million in total annual run-rate synergies from cost and capital savings. The Company expects to repurchase an additional $350 million of its common stock in 2021, exhausting the full $1.35 billion of share repurchases previously authorized.

07:14 EDT S&P Global anticipates closing IHS Markit merger in 1Q22 - S&P Global said, "The company continues to make progress on the merger with IHS Markit as the regulatory path to closing is becoming clearer. The UK and European regulators have now announced their views on the transaction. S&P Global and IHS Markit have committed to divest S&P Global's CUSIP Global Services and Leveraged Commentary and Data, together with a related family of leveraged loan indices, as well as IHS Markit's Oil Price Information Services, Coal, Metals & Mining, PetroChem Wire, and Base Chemicals businesses. Based on the regulatory feedback and these divestitures, we now anticipate closing during the first quarter of 2022."

07:12 EDT Lucira Health CHECK IT COVID-19 test kit available for online purchase - Lucira Health announced that its LUCIRA CHECK IT COVID-19 Test Kit, a self-administered PCR quality, single-use, at home molecular diagnostic test for COVID-19, is again available for online purchase. "We are excited that during the ongoing uncertainty we can again support the need for an easy to use, at home, accurate testing option that produces PCR quality results on-the-spot," said Erik Engelson, Chief Executive Officer. "We continue to see an increased need for our LUCIRA CHECK IT COVID-19 test kit and reopening our online sales channel via our website allows for greater access to our product." Each single-use test kit costs $75. The test kit, authorized for emergency use by FDA under EUA, is available over the counter, and can produce a positive result in as little as 11 minutes, or a negative result within 30 minutes. After testing, users can also access a free, text based digital LUCI PASS verified test result on their phone for work or travel.

07:11 EDT BioCryst to present new ORLADEYO data at ACAAI - BioCryst Pharmaceuticals announced that the company will present four abstracts, including one Distinguished Industry Oral Abstract, on oral, once-daily ORLADEYO for the prophylactic treatment of hereditary angioedema, HAE, at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology, ACAAI. The meeting will take place in New Orleans, Louisiana, and online, from November 4-8, 2021. "We are pleased to present additional data from our pivotal clinical trials that support how ORLADEYO is transforming the HAE treatment landscape," said Dr. William Sheridan, chief medical officer of BioCryst. "As demonstrated by the consistency in our previously reported long-term data and in real-world evidence since we launched ORLADEYO, there continues to be a strong desire among many patients to switch to an oral, once-daily prophylactic treatment to reduce the burden of treatment and increase the control of HAE attacks. We look forward to presenting our latest findings at ACAAI."

07:09 EDT Procept BioRobotics appoints Elisabeth Sandoval to board of directors - PROCEPT BioRobotics announced the appointment of Elisabeth Sandoval to its Board of Directors. Sandoval currently serves as a consultant to the pharmaceutical industry and is a member of the board of directors of Intersect ENT, Satsuma Pharmaceuticals, and Vyne Therapeutics. She is also on the Board of privately held Alastin Skincare. With the appointment of Ms. Sandoval, the Board of Directors of PROCEPT BioRobotics Corporation increased the number of directors on the Board to nine members.

07:08 EDT Hydrofarm announces closing of senior secured term loan - The Company announced that it has entered into a new $125.0 million senior secured term loan facility. The Term Loan bears interest at a rate of either LIBOR plus 5.50%, or an alternate base rate (with a 2.00% floor) plus 4.50% and matures on October 25, 2028. Hydrofarm intends to use the net proceeds from the Term Loan to fund the cash portion of the IGE purchase price and for general corporate purposes, which may include, among other things, repaying any outstanding balance under the Company's existing revolving credit facility and funding future M&A opportunities. Should additional capital needs arise, Hydrofarm can, per the terms of the Term Loan agreement, seek to upsize the facility. JPMorgan Chase Bank, N.A. acted as sole lead arranger and bookrunner for the Term Loan.

07:08 EDT Ultralife awarded $4.2M communications systems Leader Radio order - Ultralife has been awarded a purchase order valued at approximately $4.2M to supply its Vehicle Amplifier-Adaptors, VAA, to Thales Defense & Security for the U.S. Army's Leader Radio program. Shipments are expected to commence in 2022. "We are delighted to receive this follow-on order that attests to the effectiveness of our new product development strategy of designing and building technically advanced, integrated communication systems devices in collaboration with our strategic partners," said Michael Popielec, Ultralife's President and Chief Executive Officer. "With the U.S. Army's decision to go into full rate production, we look forward to our continued participation in this multi-year program."

07:07 EDT Protagonist Therapeutics earns $7.5M milestone payment from Janssen Biotech - Protagonist Therapeutics (PTGX) announced that it will receive a $7.5M milestone payment from Janssen Biotech (JNJ) triggered by the completion of the clinical data collection-related Phase 1 activities for PN-235. This investigational drug candidate is one of the three IL-23 receptor antagonists that are part of Protagonist's collaboration agreement with Janssen, which provides for concurrent development of multiple oral IL-23 receptor antagonists against a broad range of indications.

07:06 EDT EyeGate closes acquisition of Bayon Therapeutics, appoints Daniels as CDO - EyeGate Pharmaceuticals announced that it has completed the planned acquisition of Bayon Therapeutics and has appointed Eric Daniels, MD, MBA, as its Chief Development Officer, or CDO, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate's pipeline of novel treatments for eye disease. This includes overseeing the development of a potential vision-restoring small molecule from Bayon, B-203, which acts as a 'molecular photoswitch' specifically designed to restore vision in patients with inherited and age-related degenerative retinal diseases. Under the terms of the definitive agreement, EyeGate acquired all of the outstanding shares of Bayon, and Bayon became a wholly owned subsidiary of EyeGate. At closing, EyeGate issued a total of 33,798 common shares to the stockholders of Bayon, who will also be eligible to receive up to $7.1M in additional payments upon the achievement of successive milestones based on clinical trial data and regulatory approval of Bayon products. The milestone payments may be paid, at EyeGate's discretion, either in shares of common stock or in cash, subject to limitations set forth in the definitive agreement.

07:03 EDT Aslan Pharmaceuticals announces anticipated upcoming milestones - First patient enrolment in global Phase 2b trial of ASLAN004 for AD expected in the fourth quarter of 2021. Initiation of Phase 2 trial of ASLAN003 in inflammatory bowel disease expected in the first half of 2022.

06:55 EDT Crestwood Equity trading halted, news pending

06:50 EDT SQZ Biotechnologies provides update on Phase 1/2 clinical trial SQZ-PBMC-HPV-101 - SQZ Biotechnologies announced that the independent Data and Safety Monitoring Board, or DSMB, for the Phase 1/2 clinical trial SQZ-PBMC-HPV-101 has recommended that the trial advance into the combination stage with checkpoint inhibitors. In June, the company presented initial results from the first three monotherapy cohorts at the American Society of Clinical Oncology annual meeting demonstrating that the investigational cell therapy is safe and well-tolerated and can stimulate immune responses in certain patients with advanced or metastatic human papillomavirus positive tumors. Data from the highest dose monotherapy cohort has been accepted for oral presentation at the European Society for Medical Oncology Immuno-Oncology Congress being held December 8-11. The combination stage of the trial is now open for enrollment and will include checkpoint inhibitors targeting the PD-(L)1 and CTLA-4 pathways. In parallel, the company plans to continue to enroll in the highest dose monotherapy cohort.

06:48 EDT Gilead and Merck to begin Phase 2 clinical study of islatravir and lenacapavir - Gilead Sciences (GILD) and Merck (MRK), known as MSD outside the U.S. and Canada, announced the start of a Phase 2 clinical study evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy. Through the collaboration the companies seek to build on their legacies of transforming HIV care by focusing on long-acting therapies, which may represent a meaningful innovation in HIV drug development. Both islatravir and lenacapavir have long half-lives and have demonstrated activity at low dosages in independent clinical studies, which support the development as an investigational combination regimen with long-acting formulations, both oral and injectable. The Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of Merck's investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, in combination with Gilead's investigational capsid inhibitor, lenacapavir. The primary endpoint is the proportion of study participants with HIV-1 RNA viral load greater than or equal to 50 c/mL at Week 24.

06:47 EDT MSCI raises FY21 operating expense view to $955M-$975M from $920M-$940M - Cuts FY21 free cash flow view to $740M-$790M from $840M-$890M.

06:42 EDT Humanigen announces first patient dosed in PREACH-M clinical trial - Humanigen announced the first patient was dosed with lenzilumab in the Precision Approach to Chronic Myelomonocytic Leukemia, or PREACH-M, clinical trial being sponsored by the South Australian Health and Medical Research Institute, or SAHMRI, and funded by a Medical Research Future Fund grant from the National Health and Medical Research Council of the Australian government to the University of Adelaide. Humanigen is providing lenzilumab for use in the study through its Australian subsidiary, Humanigen Australia. "The prognosis for CMML is poor, with median survival of 30 months, and it has remained essentially unchanged over the past 30 years," said Associate Professor Daniel Thomas, the coordinating investigator for the trial and Associate Professor of Hematology at the University of Adelaide. "The overarching goal of the clinical trial is to improve response rates and survival. If we can improve response rates to 30%-50%, from the current 18% response rate normally seen in CMML patients treated with azacitidine, we think median survival may be increased to more than three years."

06:37 EDT Cathie Wood's ARK Investment bought about 210.6K shares of Robinhood on Monday

06:35 EDT Cathie Wood's ARK Investment bought about 235.6K shares of DraftKings on Monday

06:33 EDT Eli Lilly reports Q3 Alimta sales $457M, down 21% - The company said, "For the third quarter of 2021, worldwide Alimta revenue decreased 21 percent compared with the third quarter of 2020, to $457.0 million. U.S. revenue increased 2 percent, to $297.2 million, primarily driven by higher realized prices, partially offset by decreased demand and customer buying patterns. Revenue outside the U.S. decreased 44 percent to $159.8 million, primarily driven by decreased volume due to entry of generic competition and, to a lesser extent, lower realized prices. The company expects continued volume decline for Alimta as a result of the entry of generic competition due to the loss of patent exclusivity in Japan and major European markets. The company expects generic entrants in the U.S. beginning in the first quarter of 2022."

06:31 EDT Eli Lilly reports Q3 Trulicity sales $1.6B, up 45% - The company said, "Third-quarter 2021 worldwide Trulicity revenue was $1.600 billion, an increase of 45 percent compared with the third quarter of 2020. U.S. revenue increased 52 percent, to $1.201 billion, driven by increased demand and, to a lesser extent, higher realized prices due to segment mix, including lower utilization in the 340B program, unfavorable changes to estimates for rebates and discounts in the same period of 2020, and modest list price increases, which were partially offset by increased rebates to maintain access. Revenue outside the U.S. was $398.8 million, an increase of 26 percent, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices."

06:28 EDT Tremor International announces partnership with VIDAA for ACR data - Tremor International announced a global and exclusive strategic partnership with VIDAA, a smart TV operating system and content platform preinstalled on most TVs manufactured by Hisense, considered one of the top TV manufacturers in the world, and also integrated into a number of premium original equipment manufacturers including Toshiba. The agreement sees Tremor International's technology platform gain exclusive access to VIDAA's automatic content recognition data, both in the US and internationally. The agreement provides access to VIDAA's distribution, reaching approximately 20M smart TVs worldwide and expected to grow to more than 40M in coming years. Tremor International will bring VIDAA's ACR data into its TV Intelligence solution starting May 1, 2022, which will make Tremor International the only end-to-end technology platform with direct access to OEM ACR data for targeting purposes, outside the walled gardens. Following the integration into its TV Intelligence solution, Tremor International will have exclusive rights to the VIDAA ACR data in all global markets, and Tremor will activate in the US, Canada, UK, Germany, France, Italy, Spain, Portugal, Netherlands, Australia and Japan. The data will be available for activation by both advertiser and publisher clients, through the two pillars of Tremor International's end-to-end platform: Tremor Video and Unruly. In addition to targeting, Tremor Video and Unruly will offer proprietary measurement capabilities for TV Intelligence campaigns.

06:26 EDT General Electric CEO: Aviation building momentum, showing signs of recovery

06:25 EDT GE expects revenue growth, margin expansion, and higher free cash flow in 2022

06:24 EDT Nielsen launches Nielsen Impact Score for college athletic programs - Following the NCAA's ruling earlier this year allowing collegiate athletes to benefit from their own name, image, and likeness, Nielsen has launched a new solution, the Nielsen Impact Score, or NIS, which will help universities recruit student-athletes by demonstrating the marketing value of each athletic program. The Duke University men's basketball team, five-time national champions and 16-time Final Four participants, is the first collegiate program to sign on and use the Nielsen Impact Score.

06:23 EDT General Electric now sees FY GE Industrial free cash flow $3.75B-$4.75B - Previously forecast $3.5B-$5B.

06:22 EDT General Electric reports Q3 Industrial profit margin 5%

06:21 EDT General Electric reports Q3 total orders $22.1B, up 42%; organic orders up 42%

06:15 EDT UBS CEO: Market, economic backdrop 'broadly positive' in Q3

06:14 EDT Southside Bancshares expects positive impact from coupon redemption in Q4 - "On September 30, 2021, we redeemed our 5.5% coupon $100M subordinated notes due 2026, which will have a positive impact on our net interest margin in the Q4. We expensed $1.1M during the Q3 in connection with the redemption of the subordinated notes," stated Lee R. Gibson, President and CEO of Southside.

06:09 EDT Hercules Capital raises quarterly cash distribution to 33c per share - The distribution has a record date of November 10 with payment date of November 17.

06:06 EDT Novartis continues to expect FY21 core operating income to grow mid single digit - Novartis' 2021 group guidance is unchanged. Barring unforeseen events, the company expects net sales to grow low to mid single digit in constant currency and expects core operating income to grow mid single digit, ahead of sales, in constant currency. The company said: "Our guidance assumes that we see a continuation of the return to normal global healthcare systems including prescription dynamics, particularly oncology, in the remainder of the year. In addition, we assume that no Gilenya and no Sandostatin LAR generics enter in 2021 in the US. We are increasing our peak sales guidance for Cosentyx and Entresto, to at least $7B and at least $5B respectively."

06:01 EDT UPS raises FY21 adjusted operating margin view to 13% from 12.7% - For the full year in 2021, the company is raising its consolidated adjusted operating margin target to approximately 13.0% and expects adjusted return on invested capital to be around 29%. Capital expenditures are now planned to be approximately $4.2B and the company's effective tax rate is expected to be about 22.5%.

05:57 EDT Sensata acquires SmartWitness, terms undisclosed - Sensata announced the acquisition of SmartWitness, a privately-held video telematics technology company for commercial fleets. The SmartWitness platform is comprised of proprietary software and hardware that is built for the indirect channel of resellers and telematics service providers. The company offers connected video telematics hardware, software, analytics, and support, including interfaces with more than 40 TSPs globally. Since 2017, SmartWitness has shipped more than 250,000 connected devices to fleet customers through its telematics channel partners, making its solutions among the most widely adopted within the industry. The company's solutions are used by fleets across several market segments, including commercial trucking, federal and municipal fleets, schools and public transit networks, and military and first responder vehicles. Financial terms of the transaction were not disclosed. The transaction is subject to clearance under the Hart-Scott-Rodino Act and other customary closing conditions. Sensata and SmartWitness expect to complete the transaction during Q4.

05:35 EDT Denbury subsidiary, Mitsui subsidiary commence carbon capture evaluation - Denbury Onshore, a subsidiary of Denbury, and Mitsui E&P, a subsidiary of Mitsui, announced they have commenced a joint evaluation of potential opportunities in the U.S. Gulf Coast to develop carbon-negative oil assets utilizing anthropogenic CO2 via carbon capture, utilization, and storage. As part of the evaluation, MEPUSA and Denbury seek to jointly pursue CO2 offtake opportunities from Mitsui's potential projects along the U.S. Gulf Coast. MEPUSA will also identify international CCUS opportunities in which Denbury and MEPUSA could further collaborate.

05:31 EDT Veon, Amdocs sign agreement to enable services in Uzbekistan and Kazakhstan - Veon (VEON) and Amdocs (DOX) announced that they have signed a seven-year agreement that will enable digital services for Veon customers in Uzbekistan and Kazakhstan. The agreement is expected to lay the foundation for Veon's Beeline mobile operators in Uzbekistan and Kazakhstan to launch digital services and personalized experiences. This will happen by deploying Amdocs's microservices-based monetization and commerce suites, using technology based on cloud-ready architecture. Under the agreement, Amdocs will provide new monetization, service and network automation solutions, catalogue management, commerce and care systems, as well as enable new multi-channel front ends for digital services.

05:24 EDT Markel, MCIM announce investor support and new terms for buy-out transaction - Markel and Markel CATCo Investment Management, or MCIM announced that, following the conclusion of the early consent deadline of October 22 with respect to the buy-out transaction announced on September 27, a substantial level of investor support for the transaction has been received, with investors representing over 90% of Markel CATCo Reinsurance Fund and investors representing over 95% of CATCo Reinsurance Opportunities Fund returning support undertakings or otherwise indicating their intention to support the buy-out transaction. Each of the boards of the Private Fund and Public Fund has resolved to proceed with the commencement of schemes of arrangement in Bermuda in order to implement the buy-out transaction and will shortly issue a practice direction letter to all investors. As previously announced, the buy-out transaction will be facilitated by affiliates of Markel providing funding of up to approximately $150M to buy-out substantially all of the retrocessional segregated accounts of the funds and tail risk cover that will allow for the return of approximately $100M of trapped collateral to investors in the Private Fund's separately structured reinsurance offering, known as the Aquilo Fund segregated account. Markel Corporation has agreed certain improvements to the terms of the buy-out transaction which result in the buy-out of all segregated accounts of the funds, plus an additional cash distribution to investors by way of an increased consent fee and other cash consideration provided by Markel Corporations and its affiliates. The improved terms result in affiliates of Markel providing up to approximately $270M for the full buy-out of the funds and cash consideration of approximately $75M. Under the improved terms of the buy-out transaction, investors in the funds will still retain the right to receive any upside at the end of the applicable run-off period if currently held reserves exceed the amounts necessary to pay ultimate claims. The affiliates of Markel Corporation financing the buy-out transaction expect to receive a return of all their funding in relation to the full buy-out of the funds by the end of the run-off periods. To allow for investors who have not yet returned support undertakings to consider these improved terms, the deadline for investors to enter into an undertaking to support the buy-out transaction has now been extended to 11.59 p.m. on November 9.

05:13 EDT Digi International names Topas distributor in Germany, Switzerland and Austria - Digi International has appointed Topas as its distributor in Germany, Switzerland and Austria. Under the terms of the agreement, Digi ConnectCore system on modules, or SOM, Digi XBee RF modules, Digi Connec Me, NetSilicon & Rabbit semiconductor product portfolios will be available, complemented by support services offered by Topas.

05:08 EDT Rio Tinto, Carbfix partner on carbon capture and storage - Rio Tinto and Carbfix are partnering to implement a technology for capturing carbon and permanently storing it underground at the ISAL aluminium smelter in Iceland. Under a memorandum of understanding, or MoU, for a strategic partnership, Carbfix will use Rio Tinto's land surrounding the ISAL smelter for onshore CO2 injection in the world's first carbon mineral storage hub, the Coda Terminal. Liquified CO2 will be imported by ship from industrial sites across North Europe for storage. The companies will work together to advance carbon capture solutions that are already being tested in production cells at ISAL, with the aim of using the Carbfix technology to further decarbonize the plant. So while Rio Tinto is prioritizing emissions reductions at mines and smelters, it is also exploring the potential role of carbon capture and mineralization. Carbfix plans to drill the first injection wells for the Coda Terminal in 2022, with shipments of CO2 starting in 2025.